Oramed Pharmaceuticals (ORMP) 10-K 27 Nov 13 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Aug. 31, 2013	Nov. 25, 2013	Feb. 28, 2013
Document and Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Aug-13	'	'
Entity Registrant Name	'ORAMED PHARMACEUTICALS INC.	'	'
Entity Central Index Key	'0001176309	'	'
Current Fiscal Year End Date	'--08-31	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$52,694,028
Entity Common Stock, Shares Outstanding	'	7,947,872	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Aug. 31, 2013	Aug. 31, 2012
CURRENT ASSETS:	'	'
Cash and cash equivalents	$2,272,228	$4,430,740
Short term deposits (note 2)	5,246,627	454,381
Marketable securities (note 3)	956,376	200,311
Restricted cash (note 1o)	16,000	16,000
Prepaid expenses and other current assets (note 4)	90,103	89,998
Related parties (note 16)	4,530	404
Grants receivable from the chief scientist	58,412	84,642
T o t a l current assets	8,644,276	5,276,476
LONG TERM DEPOSITS AND INVESTMENT (note 8b)	4,593	8,867
AMOUNTS FUNDED IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT (note 7)	5,545	4,740
PROPERTY AND EQUIPMENT, net (note 5)	5,768	4,768
T o t a l assets	8,660,182	5,294,851
CURRENT LIABILITIES:	'	'
Accounts payable and accrued expenses (note 11)	450,941	597,173
Account payable with former shareholder	47,252	47,252
T o t a l current liabilities	498,193	644,425
LONG TERM LIABILITIES:	'	'
Warrants (notes 6)	'	637,182
Employee rights upon retirement (note 7)	8,004	6,959
Provision for uncertain tax position (note 15e)	23,210	228,272
Total long term liabilities	31,214	872,413
COMMITMENTS (note 8)	'	'
STOCKHOLDERS' EQUITY:	'	'
Common stock, shares issued	95,238	80,075
Accumulated other comprehensive income	303,403	'
Additional paid-in capital	29,855,723	21,589,715
Deficit accumulated during the development stage	-22,123,589	-17,891,777
T o t a l stockholders' equity	8,130,775	3,778,013
T o t a l liabilities and stockholders' equity	$8,660,182	$5,294,851

CONSOLIDATED_BALANCE_SHEETS_PA

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) (USD $)	Aug. 31, 2013	Aug. 31, 2012
CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]	'	'
Common stock, par value per share	$0.01	$0.01
Common stock, shares authorized	16,666,667	16,666,667
Common stock, shares issued	7,937,872	6,674,068
Common stock, shares outstanding	7,937,872	6,674,068

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
CONDENSED CONSOLIDATED STATEMENTS OF OPERATION [Abstract]	'	'	'
RESEARCH AND DEVELOPMENT EXPENSES, NET (note 12)	$2,271,794	$1,680,845	$11,804,488
IMPAIRMENT OF INVESTMENT	'	'	434,876
GENERAL AND ADMINISTRATIVE EXPENSES (note 13)	2,032,129	1,203,164	10,193,676
OPERATING LOSS	4,303,923	2,884,009	22,433,040
FINANCIAL INCOME (note 15a)	-180,495	-13,126	-387,653
GAIN ON SALE OF INVESTMENT	'	'	-1,033,004
IMPAIRMENT OF AVAILABLE- FOR-SALE SECURITIES	'	184,254	381,666
FINANCIAL EXPENSE (note 15b)	313,446	199,123	693,826
LOSS BEFORE TAXES ON INCOME	4,436,874	3,254,260	22,087,875
TAXES ON INCOME (note 16)	-205,062	90,218	35,714
NET LOSS FOR THE PERIOD	4,231,812	3,344,478	22,123,589
OTHER COMPREHENSIVE INCOME, NET OF TAX	'	'	'
SUBSEQUENT INCREASE IN THE FAIR VALUE OF AVAILABLE FOR SALE SECURITIES PREVIOUSLY WRITTEN DOWN AS IMPAIRED	-130,845	'	-130,845
RECLASSIFICATION ADJUSTMENT FOR GAINS INCLUDED IN NET LOSS	90,370	'	90,370
UNREALIZED GAIN ON AVAILABLE FOR SALE SECURITIES	-262,928	'	-262,928
TOTAL OTHER COMPREHENSIVE INCOME	-303,403	'	-303,403
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$3,928,409	$3,344,478	$21,820,186
BASIC AND DILUTED LOSS PER COMMON SHARE	($0.59)	($0.57)	'
WEIGHTED AVERAGE NUMBER OF COMMON SHARES USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON STOCK	7,209,283	5,884,595	'

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional paid-in capital [Member]	Other Comprehensive Income [Member]	Deficit accumulated during the development stage [Member]
BALANCE at Apr. 11, 2002	'	'	'	'	'
SHARES CANCELLED	'	($19,800)	'	'	'
SHARES ISSUED FOR INVESTMENT IN ISTI-NJ	434,876	1,144	433,732	'	'
SHARES ISSUED FOR INVESTMENT IN ISTI-NJ, shares	'	95,368	'	'	'
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	2,122,981	27,181	2,095,800	'	'
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares	'	2,265,514	'	'	'
SHARES ISSUED FOR SERVICES	98,750	125	98,625	'	'
SHARES ISSUED FOR SERVICES, shares	'	10,417	'	'	'
CONTRIBUTIONS TO PAID IN CAPITAL	18,991	'	18,991	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	1,968,547	'	1,968,547	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	177,782	'	177,782	'	'
DISCOUNT ON CONVERTIBLE NOTE RELATED TO BENEFICIAL CONVERSION FEATURE	108,000	'	108,000	'	'
IMPUTED INTEREST	8,437	'	8,437	'	'
NET LOSS	-4,478,917	'	'	'	-4,478,917
BALANCE at Aug. 31, 2007	513,131	45,231	4,946,833	'	-4,478,933
BALANCE, shares at Aug. 31, 2007	'	3,769,967	'	'	'
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	5,784,800	10,178	5,774,622	'	'
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares	'	848,288	'	'	'
SHARES ISSUED FOR SERVICES	116,110	293	115,817	'	'
SHARES ISSUED FOR SERVICES, shares	'	24,419	'	'	'
SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE	275,000	550	274,450	'	'
SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE, shares	'	45,844	'	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	459,467	'	459,467	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	203,982	'	203,982	'	'
IMPUTED INTEREST	3,780	'	3,780	'	'
NET LOSS	-2,769,271	'	'	'	-2,769,271
BALANCE at Aug. 31, 2008	4,593,060	56,252	11,785,012	'	-7,248,204
BALANCE, shares at Aug. 31, 2008	'	4,688,518	'	'	'
SHARES ISSUED FOR SERVICES	152,928	204	152,724	'	'
SHARES ISSUED FOR SERVICES, shares	'	17,012	'	'	'
SHARES TO BE ISSUED FOR SERVICES RENDERED	203,699	'	203,699	'	'
SHARES TO BE ISSUED FOR SERVICES RENDERED, shares	'	'	'	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	436,025	'	436,025	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	117,174	'	117,174	'	'
IMPUTED INTEREST	3,780	'	3,780	'	'
NET LOSS	-2,760,474	'	'	'	-2,760,474
BALANCE at Aug. 31, 2009	2,746,192	56,456	12,698,414	'	-10,008,678
BALANCE, shares at Aug. 31, 2009	'	4,705,530	'	'	'
SHARES ISSUED FOR SERVICES	249,850	1,109	248,741	'	'
SHARES ISSUED FOR SERVICES, shares	'	92,416	'	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	690,882	'	690,882	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	116,944	'	116,944	'	'
IMPUTED INTEREST	3,780	'	3,780	'	'
NET LOSS	-2,977,376	'	'	'	-2,977,376
BALANCE at Aug. 31, 2010	830,272	57,565	13,758,761	'	-12,986,054
BALANCE, shares at Aug. 31, 2010	'	4,797,946	'	'	'
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	3,694,212	11,808	3,682,404	'	'
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares	'	984,209	'	'	'
SHARES ISSUED FOR SERVICES	227,569	731	226,838	'	'
SHARES ISSUED FOR SERVICES, shares	'	60,887	'	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	502,593	'	502,593	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	26,733	'	26,733	'	'
IMPUTED INTEREST	3,782	'	3,782	'	'
NET LOSS	-1,561,245	'	'	'	-1,561,245
BALANCE at Aug. 31, 2011	3,723,916	70,104	18,201,111	'	-14,547,299
BALANCE, shares at Aug. 31, 2011	'	5,843,042	'	'	'
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	2,944,464	9,622	2,984,842	'	'
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares	'	801,942	'	'	'
SHARES AND WARRANTS TO BE ISSUED FOR CASH	25,093	'	25,093	'	'
SHARES ISSUED FOR SERVICES	107,860	349	107,511	'	'
SHARES ISSUED FOR SERVICES, shares	'	29,084	'	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	200,866	'	200,866	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	70,292	'	70,292	'	'
NET LOSS	-3,344,478	'	'	'	-3,344,478
BALANCE at Aug. 31, 2012	3,778,013	80,075	21,589,715	'	-17,891,777
BALANCE, shares at Aug. 31, 2012	6,674,068	6,674,068	'	'	'
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	1,422,592	4,192	1,418,400	'	'
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares	'	349,396	'	'	'
SHARES ISSUED FOR CASH, NET	4,238,889	7,897	4,230,992	'	'
SHARES ISSUED FOR CASH, NET, shares	'	658,144	'	'	'
SHARES TO BE ISSUED FOR SERVICES RENDERED	244,457	404	244,053	'	'
SHARES TO BE ISSUED FOR SERVICES RENDERED, shares	'	33,709	'	'	'
SHARES ISSUED FOR MARKETABLE SECURITIES	628,630	2,390	626,240	'	'
SHARES ISSUED FOR MARKETABLE SECURITIES, shares	'	199,172	'	'	'
EXCHANGE OF WARRANTS (see note 5)	917,809	'	917,809	'	'
EXERCISE OF WARRANTS	109,575	280	109,295	'	'
EXERCISE OF WARRANTS, shares	'	23,383	'	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	562,966	'	562,966	'	'
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	156,253	'	156,253	'	'
OTHER COMPREHENSIVE INCOME (LOSS)	303,403	'	'	303,403	'
NET LOSS	-4,231,812	'	'	'	-4,231,812
BALANCE at Aug. 31, 2013	$8,130,775	$95,238	$29,855,723	$303,403	($22,123,589)
BALANCE, shares at Aug. 31, 2013	7,937,872	7,937,872	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($4,231,812)	($3,344,478)	($22,123,589)
Adjustments required to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	5,379	14,737	126,223
Amortization of debt discount	'	'	108,000
Exchange differences	19,179	62,494	50,216
Stock based compensation	719,219	271,158	5,690,506
Common stock issued for services	244,457	107,860	1,400,413
Gain on sale of investment	-50,703	'	-1,083,707
Impairment of investments	'	'	434,876
Impairment of available for sale securities	'	184,254	381,666
Imputed interest	'	'	23,559
Exchange of warrants	296,982	'	296,982
Changes in fair value of warrant liabilities	-44,699	142,704	98,005
Changes in operating assets and liabilities:	'	'	'
Prepaid expenses and other current assets	-3,094	-31,199	-163,253
Restricted cash	'	'	-16,000
Accounts payable and accrued expenses	-146,232	203,133	450,941
Liability of employee rights upon retirement	1,045	-2,489	21,231
Provision for uncertain tax position	-205,062	90,218	23,210
Total net cash used in operating activities	-3,395,341	-2,301,608	-14,280,721
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Purchase of property and equipment	-6,379	-2,129	-131,991
Purchase of short term deposits	-5,846,628	-475,353	-11,750,363
Proceeds from sale of short term deposits	1,054,011	1,800,000	6,482,011
Proceeds from sale of investment and marketable securities	226,671	450,000	676,671
Funds in respect of employee rights upon retirement	-2,090	-3,620	-8,985
Lease deposits	4,894	'	-2,615
Total net cash provided by (used in) investing activities	-4,569,521	1,768,898	-4,735,272
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock and warrants - net of issuance expenses	5,714,918	3,488,942	20,859,553
Proceeds from exercise of warrants and options	109,575	'	109,575
Receipts on account of shares issuances	'	'	6,061
Proceeds from convertible notes	'	'	275,000
Proceeds from short term note payable	'	'	120,000
Payments of short term note payable	'	'	-120,000
Shareholder advances	'	'	66,243
Net cash provided by financing activities	5,824,493	3,488,942	21,316,432
EFFECT OF EXCHANGE RATE CHANGES ON CASH	-18,143	-38,857	-28,211
INCREASE IN CASH AND CASH EQUIVALENTS	-2,158,512	2,917,375	2,272,228
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	4,430,740	1,513,365	'
CASH AND CASH EQUIVALENTS AT END OF PERIOD	2,272,228	4,430,740	2,272,228
Material non cash investing and financing activities:	'	'	'
Discount on convertible note related to beneficial conversion feature	'	'	108,000
Shares and warrants issued for offering costs	'	'	77,779
Contribution to paid in capital	'	'	18,991
Exchange of warrants	917,809	'	917,809
Shares and warrants issued for marketable securities	628,630	'	628,630
Shares and warrants to be issued for cash	'	$25,093	'

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Aug. 31, 2013
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 1 -  SIGNIFICANT ACCOUNTING POLICIES:
		a.	General
		1)	Incorporation and operations
			Oramed Pharmaceuticals Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd ("Hadasit") to acquire the provisional patent related to orally ingestible insulin pill to be used for the treatment of individuals with diabetes. In subsequent periods, the Company entered into additional development agreements with Hadasit, the most recent of which was signed on September 11, 2011, see also note 8a.
			On March 11, 2011, the Company was reincorporated from the State of Nevada to   the State of Delaware.
			On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term "Group" refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the "Subsidiary"), (together with the Company, "the Group").
			In March 2011, the Subsidiary sold shares of its investee company, Entera Bio Ltd ("Entera") to D.N.A Biomedical Solutions Ltd ("D.N.A"), remaining a 3% interest, which is accounted for as a cost method investment (amounting $1,027). In consideration for the shares sold to D.N.A, the Company received a promissory note issued by D.N.A in the principal amount of $450,000, with an annual interest rate of 0.45%, that was paid in full in November 2011, and 8,404,667 ordinary shares of D.N.A, see also note 3.
			As part of this agreement, the Subsidiary entered into a patent transfer agreement according to which, the Subsidiary assigned to Entera all of its right, title and interest in and to the patent application that it has licensed to Entera since August 2010.  Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera's net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. As of August 31, 2013, Entera had not yet realized any revenues and had not paid any royalties to the Subsidiary.
		2)	Development and liquidity risks
			The Company has been in the development stage since its formation and has not yet generated any revenues from its operations.
			The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with the ASC Topic 915 "Development Stage Entities" due to the fact that it has not generated any revenues from its operations.
	Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.
	Based on its current cash resources and commitments, and cash received in private and public offerings in the year ended August 31, 2013, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months and beyond, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.
		3)	Reverse stock split
	On January 10, 2013, the Company's Board of Directors approved a reverse stock split at a ratio of one-for-twelve, effective January 22, 2013, which decreased the number of common shares issued and outstanding as of January 23, 2013, from approximately 86.5 million shares to approximately 7.2 million shares and the number of authorized common shares from 200 million shares to approximately 16.7 million shares. All share and per share amounts included in the consolidated financial statements have been adjusted retroactively to reflect the effects of the reverse stock split.
		b.	Accounting principles
		The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP").
		c.	Use of estimates in the preparation of financial statements
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates.
	As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock based compensation, valuation and impairment of marketable securities and valuation of tax exposures.
		d.	Functional currency
	The currency of the primary economic environment in which the operations of the Group are conducted is the U.S. dollar ("$" or "dollar"). Therefore, the functional currency of the Group is the dollar.
	Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions - exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate.
		e.	Principles of consolidation
	The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation.
		f.	Property and equipment
	Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the assets.
	Annual rates of depreciation are as follows:
			%
	Computers and peripheral equipment			33
	Office furniture and equipment			15-33
	Leasehold improvements are amortized over the term of the lease which is shorter than the estimated useful life of the improvements.
		g.	Income taxes
	1. Deferred taxes
	Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets.
	Regarding the Subsidiary, the recognition is prohibited for deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities.
	Taxes that would apply in the event of disposal of investments in the subsidiary have not been taken into account in computing deferred taxes, as it is the Company's intention to hold this investment, not to realize it.
	2.  Uncertainty in income tax
	The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company's policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses.
		h.	Research and development, net
	Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, costs of registered patents materials, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company's clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred.
	Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company out sources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.
	Grants received from the OCS and Bio-Jerusalem are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grants are deducted from the related research and development expenses as the costs are incurred and are presented in R&D expenses, net. See also notes 8(k) and 8(l).
		i.	Cash equivalents
	The Company considers all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.
		j.	Loss per common share
	Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding and shares relating to receipts on account of shares in equity during the period. Outstanding stock options and  warrants have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options and warrants excluded from the calculation of diluted net loss was 2,343,972 for the year ended August 31, 2013 (1,892,180 for the year ended August 31, 2012). The computation of  basic and diluted net loss per common share was adjusted retroactively for all periods presented to reflect the Company's reverse stock split. See also note 1a(3).
		k.	Impairment in value of long-lived assets
	The Company reviews long-lived assets, to be held and used, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. In the event the sum of the expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment loss would be recognized, and the assets are written down to their estimated fair values
		l.	Stock based compensation
	Equity awards granted to employees are accounted for using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimated forfeitures based on historical experience and anticipated future conditions.
	The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. When stock options are granted as consideration for services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the consideration received or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.
		m.	Warrants issued as part of capital raisings that are classified as a liability
	Warrants that entitle the holder to down-round protection (through ratchet and anti-dilution provisions) are classified as liabilities in the statement of financial position.
	The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net. See note 6.
		n.	Fair value measurement:
	Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:
		Level 1:	Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
		Level 2:	Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
		Level 3:	Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	As of August 31, 2013 the assets or liabilities measured at fair value comprise of available for sale securities (level 1).
	In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent.
	In order to secure the fulfillment of the Company's obligations under the derivatives agreements, the Company has placed a restricted deposit with the bank in an amount of $16,000.
Available-for-sale securities are reported at fair value, with unrealized gains and losses, net of related tax recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.
The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company's ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses.
	o.	Concentration of credit risks
Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, deposit and short term investments which are deposited in major financial institutions. The Company is of the opinion that the credit risk in respect of these balances is remote.
	p.	Newly issued  and recently adopted accounting pronouncements:
	1	In June 2011, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update (ASU) 2011-05, an update to ASC No. 220, "Presentation of Comprehensive Income," which eliminates the option to present other comprehensive income and its components in the statement of shareholders' equity. The Company can elect to present the items of net income and other comprehensive income in a single continuous statement of comprehensive income or in two separate, but consecutive, statements. Under either method the statement would need to be presented with equal prominence as the other primary financial statements. The amended guidance, which must be applied retroactively, is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, with earlier adoption permitted. In December 2011, the FASB issued another update on the topic, which deferred the effective date pertaining only to the presentation of reclassification adjustments on the face of the financial statements. The Company adopted the pronouncement in the first quarter of fiscal year 2013.
	2	In February 2013, the FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU 2013-02"). This update requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, ASU 2013-02 requires presentation, either on the face of the income statement or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by respective line items of net income, but only if the amounts reclassified are required to be reclassified in their entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about these amounts. The amendments in ASU 2013-02 will be effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. The accounting update will be applicable to the Company beginning in the first quarter of fiscal year 2014. The Company does not expect the adoption of ASU 2013-02 to have a material effect on the consolidated financial statement presentation.
	3	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (ASU 2013-11). This update requires an entity to present  in the financial statements  an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The assessment of whether a deferred tax asset is available is based on the unrecognized tax benefit and deferred tax asset that exist at the reporting date and should be made presuming disallowance of the tax position at the reporting date. The amendments in ASU 2013-11 will be effective prospectively for annual reporting periods beginning after December 15, 2013, and interim periods within those annual periods. The accounting update will be applicable to the Company beginning in the first quarter of fiscal year 2015.  The Company does not expect the adoption of ASU 2013-11 to have a material effect on the consolidated financial statement presentation.

SHORT_TERM_INVESTMENTS

SHORT TERM INVESTMENTS	12 Months Ended
	Aug. 31, 2013
SHORT TERM INVESTMENTS [Abstract]	'
SHORT TERM INVESTMENTS	'
	NOTE 2 - SHORT TERM DEPOSITS:
	Amounts that represent bank deposits that do not meet the cash equivalent criteria are the following:
		31-Aug
		2013				2012
		Annual interest rate		Amount		Annual		Amount
						interest rate
	Dollar deposits		0.6-1.06%	$	5,111,914		0.85%	$	260,371
	NIS deposits		1.93%		134,713		1.93-1.97%		194,010
				$	5,246,627			$	454,381

MARKETABLE_SECURITIES

MARKETABLE SECURITIES	12 Months Ended
	Aug. 31, 2013
MARKETABLE SECURITIES [Abstract]	'
MARKETABLE SECURITIES	'
	NOTE 3 - MARKETABLE SECURITIES:
	During the reporting period, marketable securities consist wholly of equity securities of D.N.A, which were received in March 2011 as part of the consideration for selling the shares of Entera, see also note 1a(1), and in October 2012, as an option to purchase ordinary shares of D.N.A with no additional costs in exchange for the Company's common stock (the "D.N.A Option"), see also note 9e. The D.N.A Option was exercised by the Company in February 2013 for 21,637,611 shares of D.N.A. Pursuant to Tel Aviv Stock Exchange ("TASE") policy regarding private placements, trading of such shares was restricted until August 2013. Until August 26, 2013, the fair value of the restricted securities was measured based on the quoted prices of the otherwise identical unrestricted securities, adjusted for the effect of the restriction by applying a proper discount. The discount was determined with reference to other similar restricted instruments. Similar securities, with no restriction on tradability, are quoted on an active market.
	As of August 31, 2013 the securities were reclassified to level 1, since the restriction period was over. Those securities are classified as available-for-sale and are recorded at fair value.
	On February 14, 2013 the Subsidiary sold 3,500,000 of the D.N.A shares in a private transaction for a total of NIS 420,000 (or approximately $114,130). On March 5, 2013 each of the Subsidiary and the Company sold additional 1,750,000 of their D.N.A shares in a private transaction for a total of NIS 420,000 (or approximately $112,540).
	The cost of the securities sold and the amount reclassified out of accumulated other comprehensive income into net loss, were determined by specific identification.
	The shares are traded on the TASE and have a quoted price. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.
	Financial assets carried at fair value as of August 31, 2013 and 2012 are classified as level 1 as described in the table below:
		Level 1
	Marketable securities:
	31-Aug-13	$	956,376
	31-Aug-12	$	200,311
	As of August 31, 2013 the Group owns approximately 11.1% of D.N.A's outstanding ordinary shares. For information regarding sales of D.N.A shares by the Group after balance sheet date, see note 17a.
	Transfers in and/or out of level 3 are recognized in the beginning of the reporting period.
	The following table summarizes the activity for those financial assets where fair value measurements are estimated utilizing Level 3 inputs:
		31-Aug
		2013			2012
	Carrying value at the beginning of the period	$	-		$	384,565
	Additions		628,630			-
	Reclassification to level 1		(628,630	)		(384,565	)
	Carrying value at the end of the period	$	-		$	-
	As of August 31, 2013, the carrying amount of cash and cash equivalents, short term deposits, accounts receivable, other current assets and accounts payables and accrued expenses approximates their fair values due to the short-term maturities of these instruments.
	The fair value of long-term deposits also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

PREPAID_EXPENSES_AND_OTHER_CUR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Aug. 31, 2013
PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]	'
PREPAID EXPENSES AND OTHER CURRENT ASSETS	'
	NOTE 4 - PREPAID EXPENSES AND OTHER CURRENT ASSETS:
	Composition of prepaid expenses and other current assets, grouped by major classifications, is as follows:
		31-Aug
		2013		2012
	Tax Authorities	$	59,898	$	53,341
	Prepaid expenses and other  receivables		30,205		36,657
		$	90,103	$	89,998

PROPERTY_AND_EQUIPMENT_NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Aug. 31, 2013
PROPERTY AND EQUIPMENT, Net [Abstract]	'
PROPERTY AND EQUIPMENT, Net	'
	NOTE 5 - PROPERTY AND EQUIPMENT, NET:
		a.	Composition of property and equipment, grouped by major classifications, is as follows:
			31-Aug
			2013		2012
	Cost:
	Leasehold improvements		$	76,029	$	76,029
	Office furniture and equipment			19,941		19,941
	Computers and peripheral equipment			34,301		29,642
				130,271		125,612
	Less - accumulated depreciation and amortization			124,503		120,844
			$	5,768	$	4,768
		b.	Depreciation expenses totaled $5,379 and $14,737 in the years ended August 31, 2013 and 2012, respectively.

WARRANTS

WARRANTS	12 Months Ended
	Aug. 31, 2013
WARRANTS [Abstract]	'
WARRANTS	'
	NOTE 6 - WARRANTS
	As part of the Company's private placements, warrants were granted to the Leading Investor, as defined in note 9c. Warrants to purchase 182,292 shares were granted in January 2011 (the "2011 Warrants"), warrants to purchase 112,613 shares were granted in August 2012 (the "August 2012 Warrants") and warrants to purchase 16,892 shares were granted in November 2012 (together, with the 2011 Warrants and the August 2012 Warrants, the "Three Warrants"). Each warrant was granted for five years at an initial exercise price of $6.00 per share. The warrants included a full ratchet anti-dilution protection from the second year anniversary date after issuing the warrant, subject to certain limitations and while the warrant was outstanding.  In the event the Company was to issue or sell any common stock for a consideration per share lower than the exercise price then in effect, or was to issue or sell any options, warrants or other rights for the purchase or acquisition of such shares at a consideration per share of less than the exercise price then in effect, the warrants were to be amended to (a) reduce the exercise price to an amount equal to the per share consideration payable to the company in such sale or issuance, and (b) the quantity of warrants were to be updated, based on certain rules as determined in the Warrants Agreements with the Leading Investor.
	As a result of a private placement in August 2012, and pursuant to adjustment of the terms of the 2011 Warrants, such warrants were amended to: (i) reduce the exercise price from $6.00 to $4.44, (ii) increase the number of shares issuable upon the exercise of the warrant from 182,292 to 246,341.
	In addition, as a result of the agreement with D.N.A from October 2012, as described in note 9e, and pursuant to adjustment terms of the 2011 Warrants, the Company further amended the 2011 Warrants by: (i) reducing the exercise price from $4.44 to $3.7656 and (ii) increasing the number of shares issuable upon the exercise of the 2011 Warrants from 246,341 to 290,459.
	On November 29, 2012, the Company and the Leading Investor entered into a letter agreement (the "Agreement") in connection with the Three Warrants. Pursuant to the Agreement, the Company and the Leading Investor agreed to amend the Three Warrants to provide that the anti-dilution protection of each of the Three Warrants shall be removed in its entirety. In addition, as to the Warrants issued in August and November 2012, the parties agreed that the exercise price shall be reduced to $3.7656. On that day, the Company also issued to the Leading Investor a Common Stock Purchase Warrant (the "New Warrant") pursuant to which, the Leading Investor shall have the right to purchase up to 137,311 shares of the Company over a period of four years at an exercise price of $7.20 per share. The fair value of the New Warrant at the date of grant was $145,173, using the following assumptions: dividend yield of 0% , expected term of 4 years, expected volatility of 62.29% and risk-free interest rate of 0.57%.
	The fair value of the warrants was determined by using a Monte Carlo type model based on the risk neutral approach. The significant unobservable input used in the fair value measurement is the future expected issue dates. Significant delay in this input would result a higher fair value measurement.
	In addition to the New Warrant, Nadav Kidron, the Company's President, Chief Executive Officer and director, in his personal capacity as a shareholder of the Company, undertook and agreed that following the execution and delivery of the Agreement, in the event that an adjustment pursuant to the anti-dilution protection of any of the Three Warrants (had it not been amended by the Agreement thereof) would have been triggered and the number of shares of common stock of the Company that the Leading Investor would have been able to purchase under the Three Warrants would have increased by an aggregate number in excess of 137,311 shares, then the Leading Investor shall have the right to purchase from Mr. Kidron such number of shares of common stock of the Company owned by Mr. Kidron equal to such excess, up to a maximum of 112,690 shares of common stock of the Company (the "Kidron Option"). The foregoing right shall survive until the expiration date of such Three Warrants. The fair value of the Kidron Option on the date of grant was $168,220, based on the Monte Carlo type model and was recognized as an expense against the stockholders equity.
	Following the removal of the anti-dilution protection, the Three Warrants were no longer classified as liabilities. The Company recognized a financial expense in the amount of $296,982 during the three months ended November 30, 2012.
	Financial liabilities carried at fair value as of August 31, 2013 and 2012, are classified in the table below in one of the three fair value categories:
		Fair value measurements at reporting
		date using
		Level 3			Total
	Warrants -
	31-Aug-13	$	-		$	-
	31-Aug-12	$	637,182		$	637,182
	The following table summarizes the activity for those financial liabilities where fair value measurements are estimated utilizing Level 3 inputs:
		Year ended August 31,			Year ended August 31,
		2013			2012
	Carrying value at the beginning of the period	$	637,182		$	-
	Additional warrant liabilities granted		28,344			494,478
	Changes in fair value		(44,699	)		142,704
	Exchange of warrants		(620,827	)		-
	Carrying value at the end of the period	$	-		$	637,182

EMPLOYEES_RIGHTS_UPON_RETIREME

EMPLOYEES RIGHTS UPON RETIREMENT	12 Months Ended
	Aug. 31, 2013
EMPLOYEE RIGHTS UPON TERMINATION [Abstract]	'
EMPLOYEE RIGHTS UPON TERMINATION	'
	NOTE 7 - EMPLOYEES RIGHTS UPON RETIREMENT:
	The Subsidiary is required to make a severance payment upon dismissal of an employee, or upon termination of employment in certain circumstances.  The severance pay liability to the employees (based upon length of service and the latest monthly salary - one month's salary for each year employed) is recorded on the Subsidiary's balance sheets under "Liability for employee rights upon retirement."  The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.
	The liability is funded in part by the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds.  The amounts used to fund these liabilities are included in the Subsidiary's balance sheets under "Funds in respect of employee rights upon retirement."  These policies are the Subsidiary's assets.  However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited.  In the years ended August 31, 2013 and 2012, the Subsidiary deposited $2,090 and $3,620, respectively, with insurance companies in connection with its severance payment obligations.
	In accordance with the current employment agreements with certain employees, the Subsidiary  makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's rights upon retirement.  The Subsidiary  is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee.  The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Subsidiary's balance sheets, as the amounts funded are not under the control and management of the Subsidiary  and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the "Contribution Plans").
	The amounts of severance pay expenses were $23,331 and $5,615 for the years ended August 31, 2013 and 2012, respectively. $12,592 and $7,089 in the years ended August 31, 2013 and 2012, respectively, were in respect of a Contribution Plan.
	The Subsidiary expects to contribute approximately $25,480 in the year ending August 31, 2014 to insurance companies in connection with its severance liabilities for its operations for that year, $22,835 of which will be contributed to one or more Contribution Plans.

COMMITMENTS

COMMITMENTS	12 Months Ended
	Aug. 31, 2013
COMMITMENTS [Abstract]	'
COMMITMENTS	'
	NOTE 8 - COMMITMENTS:
		a.	On September 11, 2011, the Subsidiary entered into an agreement with Hadasit,   Dr. Miriam Kidron and Dr. Daniel Schurr (the "Agreement"), to retain consulting and clinical trial services. According to the Agreement, Hadasit will be entitled to a consideration of $200,000 to be paid by the Company in accordance with the actual progress of the study, $50,000 of which were paid and recognized through August 31, 2013. See also note 1a(1).
		b.	The Subsidiary has entered into operating lease agreements for vehicles used by its employees for a period of 3 years.
	The lease expenses for the years ended August 31, 2013 and 2012 were $29,603 and $29,543, respectively.
	The future lease payments under the lease agreement are $24,603, $17,615 and $7,340 for the years ending August 31, 2014, 2015 and 2016, respectively.
	As security for its obligation under the lease agreements the Subsidiary deposited $1,959, which are classified as long term deposits.
		c.	On July 5, 2010, the Subsidiary of the Company entered into a Manufacturing Supply Agreement ("MSA")  with Sanofi-Aventis Deutschland GMBH ("Sanofi"). According to the MSA, Sanofi will supply the subsidiary with specified quantities of recombinant human insulin to be used for clinical trials in the United States.
		d.	On February 15, 2011, the Subsidiary entered into a consulting agreement with a third party (the "Consultant") for a period of five years, pursuant to which the Consultant will provide consultation on scientific and clinical matters. The Consultant is entitled to a fixed monthly fee of $8,000, royalties of 8% of the net royalties actually received by the Subsidiary in respect of the patent that was sold to Entera on March 31, 2011 (see note 1a(1)) and an option to purchase up to 20,834 shares of the Company at an exercise price of $6.00 per share. The option vests in five annual installments commencing February 16, 2012 and expires on February 16, 2021. The initial fair value of the option on the date of grant was $62,185, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 78.65%; risk-free interest rates of 3.62%; and the remaining expected term of 10 years. The fair value of the option as of August 31, 2013 was $108,675, using the following assumptions: dividend yield of 0% and expected term of 7.46 years; expected volatility of 76.87%; and risk-free interest rate of 2.33%.  The fair value of the option granted is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.
		e.	On July 25, 2011, the Company issued warrants to purchase 32,000 shares of the Company at an exercise price of $6.00 per share to a third party as remuneration for services to be rendered during the 12 month period commencing May 13, 2011. The warrants vest in twelve equal installments over the five years period form October 13, 2011 to May 13, 2016, and will expire on July 25, 2016. The fair value of these warrants on the date of grant was $5,057, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 77.39%; risk-free interest rate of 1.55%; and the remaining expected term of 5 years. The fair value of the option as of August 31, 2013, was $9,169, using the  following assumptions: dividend yield of 0% and expected term of 2.9 years; expected volatility of 76.41%; and risk-free interest rate of 0.79%. The fair value of the option granted is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.
		f.	On February 15, 2012, the Company entered into an advisory agreement with a third party for a period of one year, pursuant to which such third party will provide investors relations services and will be entitled to a share based compensation as follows: 25,000 shares of the Company will be issued in six installments over the engagement period, commencing February 15, 2012, and a warrant to purchase 62,500 shares of the Company at an exercise price of $6.00 per share. The warrant vested in 12 monthly installments commencing February 15, 2012 and expires on February 15, 2017. The initial fair value of the warrant on the date of grant was $121,304, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.82%; risk-free interest rates of 0.81%; and the remaining expected term of 5 years.
	On July 3, 2012, the Company and the third party entered into an amendment to the agreement, according to which the original agreement was extended until July 3, 2013, and a new vesting schedule was determined for the remainder of the share based compensation until July 3, 2013. The change in the vesting schedule did not have any material effect on the expenses related to this advisory agreement. The Company records expenses in respect of this warrant during the term of the services.
	The fair value of the warrant as of June 15, 2013, the date of the last vesting installment, was $164,752, using the following assumptions: dividend yield of 0% and expected term of 4.0 years; expected volatility of 76.16%; and risk-free interest rate of 0.77%. The fair value of the warrant granted is recognized over the related service period using the straight-line method.
		g.	On March 18, 2012, the Subsidiary entered into a lease agreement for its facilities in Israel. The lease agreement is for a period of 57 months commencing January 1, 2012.
	The annual lease expenses for the years ended August 31, 2013 and 2012 were approximately $13,116 and $9,132, respectively.
	On April 28, 2013, the Subsidiary entered into a new lease agreement for its office facilities in Israel. The new lease agreement is for a period of 36 months commencing October 1, 2013. The annual lease payment will be NIS 89,052 from 2014-2016, and will be linked to the increase in the Israeli consumer price index (as of August 31, 2013, the future annual lease payments under the new agreement will be $24,641, based on the exchange rate as of August 31,2013).
	As security for its obligation under this lease agreement the Company provided a bank guarantee in an amount equal to three monthly lease payments.
		h.	On April 15, 2013, the Company entered into a consulting agreement with a third party advisor for a period of twelve months, pursuant to which such advisor provided investor relations services and received a monthly cash fee and 15,000 shares of the Company to be issued in three equal installments, on  each of May 1, 2013, August 1, 2013 and November 15, 2013. On July 11, 2013 the Company issued to such advisor 5,000 shares. The fair value of the shares at this date was $34,900. The Company issued the remaining 10,000 shares on November 4, 2013, see also note 9f.
		i.	On April 29, 2013, the Subsidiary entered into a Clinical Research Organization Service Agreement with a third party, to retain it as a CRO, for its Phase 2a clinical trial for an oral insulin capsule. As consideration for its services, the subsidiary will pay the CRO a total amount of approximately $332,702 that will be paid during the term of the engagement and based on achievement of certain milestones, $89,830 of which were paid and recognized through August 31, 2013.
		j.	On July 23, 2013, the Subsidiary entered into a Master Service Agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $102,280, of which $30,684 were paid and recognized through August 31, 2013.
		k.	Grants from Bio-Jerusalem
	The Subsidiary is committed to pay royalties to the Bio-Jerusalem fund on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $65,053.  As of August 31, 2013, the Subsidiary had not yet realized any revenues and did not incur any royalty liability.
	During the year ended August 31, 2013,  the Company received $12,319 from the Bio-Jerusalem fund. For the period from inception on April 12, 2002 through August 31, 2013, the research and development expenses are presented net of Bio-Jerusalem grants, in the total amount of $65,053.
		l.	Grants from the Chief Scientist Office ("OCS")
	Under the terms of the Company's funding from the Israeli Government, royalties of 3%-3.5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of annual interest at a rate based on LIBOR.
	At the time the grants were received, successful development of the related projects was not assured. In case of failure of a project that was partly financed as above, the Company is not obligated to pay any such royalties.
	On August 31, 2013, the Subsidiary had not yet realized any revenues from the said project and did not incur any royalty liability. The total amount that was actually received through August 31, 2013 was $1,659,338.
	For the years ended August 31, 2013, and 2012, and for the period from inception on April 12, 2002 through August 31, 2013, the research and development expenses are presented net of OCS Grants, in the total amount of $296,836, $372,959 and $1,717,392, respectively.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Aug. 31, 2013
STOCK HOLDERS' EQUITY [Abstract]	'
STOCK HOLDERS' EQUITY	'
	NOTE 9 - STOCKHOLDERS' EQUITY:
	In February 2013 the Company's common stock began trading on the Nasdaq Capital Market under the symbol ORMP. Before then it was traded on the Over-The-Counter Bulletin Board.
	The following are capital stock transactions that took place during the years ended August 31, 2013 and 2012:
		a.	On August 15, 2011, the Company entered into a consulting agreement with a third party advisor for a period of nine months, pursuant to which such advisor provided investor relations services and received a monthly cash fee and shares of the Company's  that were issued in three equal installments as follows: on  each of December 12, 2011, March 14, 2012 and May 15, 2012, the Company issued 6,917 shares at a fair value of $24,900, $26,560 and $24,900, respectively.
		b.	Under the terms of the advisory agreement, as described in note 8f, on  each of March 14, 2012 and July 5, 2012, the Company issued 4,167 shares to such advisor as remuneration for services provided. The fair value of the shares at the dates of grant was $15,500 and $16,000, respectively. The Company issued the remaining 16,667 shares on July 30, 2013 at a fair value of $123,336.
		c.	In August 2012, the Company entered into Securities Purchase Agreements with a number of investors for the sale of 801,942 units at a purchase price of $4.44 per unit for total consideration of $3,560,192. Each unit consisted of one share of the Company and one common stock purchase warrant. Each warrant entitles the holder to purchase half a share exercisable for five years at an exercise price of $6.00 per share.  The investors were granted customary registration rights with respect to resales of shares, including the shares underlying the warrants. In addition, one of the investors who was previously defined as a leading investor (the "Leading Investor"), who purchased 225,226 of the units, was granted the right to maintain its percentage of the shares of the Company's common stock outstanding by purchasing more shares whenever the Company proposes to issue certain additional shares to other investors.  Such right only exists so long as such investor holds at least 5% of the Company's outstanding common stock.  In addition, such investor's warrants contained anti-dilution protection (the "full ratchet anti-dilution protection") and cashless exercise provisions not contained in the other investors' warrants.  The other terms of the Leading Investor's Securities Purchase Agreement were substantially the same as those granted to him in 2011 for his first investment. As to the amendment to the 2011 Warrants, see note 6.
			In addition, in August 2012, the Company entered into a Securities Purchase Agreement with an investor for the sale of 5,652 units at same terms as describe above. As the payment from said investor was received during September 2012, following which, the Company issued him 5,652 shares of its common stock and a warrant to purchase 2,826 shares of its common stock, the proceeds from that investment, of $25,093 were presented as shares and warrants to be issued for cash.
			The Company paid cash consideration of $71,250 as finders' fees in connection with the Securities Purchase Agreements.
		d.	Between September and November 2012, the Company entered into Securities Purchase Agreements with a number of investors for the sale of 329,872 units at a purchase price of $4.44 per unit for total consideration of $1,464,425. Each unit consisted of one share of the Company's common stock and one common stock purchase warrant. Each warrant entitles the holder to purchase 0.50 a share of common stock exercisable for five years at an exercise price of $6.00 per share. The investors were granted customary registration rights with respect to resales of shares, including the shares underlying the warrants. The Leading Investor purchased 33,784 of the units and was granted the same rights as described in note 9c above. See also note 6 regarding the removal of the full ratchet anti-dilution protection.
	As a finder's fee, in connection with the securities purchase agreements, the Company paid   cash consideration of $12,885, as well as issued 1,127 shares of the Company and 564 common stock purchase warrant to another individual. The Company also issued 12,745 shares of the Company and 6,373 common stock purchase warrants to a director as a finder's fee with respect to the Securities Purchase Agreements described above and to the Securities Purchase Agreements to which the Company had entered into in August 2012.
		e.	On October 30, 2012, the Company entered into a Securities Purchase Agreement with D.N.A, according to which, the Company issued on that day to D.N.A 199,172 shares of its common stock, in consideration for the option to purchase up to 21,637,611 ordinary shares of D.N.A, valued at approximately $628,630 at the day of the transaction. The Company exercised the option in February 2013. See also note 3.
		f.	As  described in note 8h, on  July 11, 2013, the Company issued 5,000 shares of its common stock to an advisor as remuneration for services rendered.
		g.	On  July 10, 2013, the Company entered into a Placement Agency Agreement with Aegis Capital Corp. as representative of the several placement agents (the "Placement Agents"), pursuant to which the Placement Agents agreed to use their reasonable best efforts to arrange for the sale of up to 658,144 shares of the Company's common stock.  In connection therewith, on July 10, 2013, the Company also entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell an aggregate of 658,144 shares at a price of $7.00 per share, to various investors in a registered direct offering (the "Offering"). The Company had received all funds and issued all shares in connection with the Offering as of July 17, 2013. The net proceeds to the Company from the offering are approximately $4,238,889, after deducting Placement Agents' commissions of $255,246 and other offering expenses of the Company.
		h.	On July 8,2013, the Company issued 12,042 shares to four service providers as remuneration for investors relations services provided during the year ended August 31, 2013. The total fair value of the shares at the date of grant was $86,221.
		i.	As to shares issued as part of stock based compensation plan see note 10.

STOCKBASED_COMPENSATION

STOCKBASED COMPENSATION	12 Months Ended
	Aug. 31, 2013
STOCK BASED COMPENSATION [Abstract]	'
STOCK BASED COMPENSATION	'
	NOTE 10 - STOCK BASED COMPENSATION:
	As of August 31, 2013, the Company has one stock option plan (the "2008 Stock Option Plan"), under which, the Company had reserved a pool of 1,000,000 shares of the Company's common stock which may be issued at the discretion of the Company's Board of Directors from time to time. Under this Plan, each option is exercisable into one share of common stock of the Company.
	The options may be exercised after vesting and in accordance with vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of the options is 10 years.
	The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility is based on a historical volatility, by statistical analysis of the weekly share price for past periods. The expected term is the length of time until the expected dates of exercising the options, based on estimated data regarding employees' exercise behavior.
	The following are stock options transactions made during the years ended August 31, 2013 and 2012:
		a.	On August 8, 2012, options to purchase an aggregate of 144,000 shares of the Company were granted to Nadav Kidron, the Company's President, Chief Executive Officer and director, and Miriam Kidron, the Company's Chief Medical and Technology Officer and director, both related parties, at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant), the options vested with respect to 42,000 shares of common stock immediately on the date of grant and the remaining shares of common stock will vest in seventeen equal monthly installments of 6,000 each. These options expire on August 7, 2022.  The fair value of these options on the date of grant was $373,565, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 0.83%; and expected term of 5.5 years.
		b.	On August 8, 2012, options to purchase an aggregate of 43,334 shares of the Company were granted to three Board of Directors members at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant). The options vest in two equal annual installments, commencing January 1, 2013, and expire on August 7, 2022. The fair value of these options on the date of grant was $114,694, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 1.0375%; and expected term of 5.75 years.
		c.	On August 8, 2012, options to purchase 50,750 shares of the Company were granted to an employee of the Subsidiary, at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant). The options vest in 29 equal monthly installments, commencing August 31, 2012, and expire on August 8, 2022. The fair value of these options on the date of grant was $134,324, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 1.0375%; and expected term of 5.75 years.
		d.	On August 8, 2012, options to purchase 6,250 shares of the Company c granted to an employee of the Subsidiary, at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant). The options vest in three equal annual installments, commencing January 1, 2013, and expire on August 7, 2022. The fair value of these options on the date of grant was $16,780, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 0.935%; and expected term of 6 years.
		e.	August 8, 2012, the Company's Board of Directors approved an extension of the term of the warrants to purchase 280,114 shares of the Company held by Dr. Miriam Kidron by approximately two years from such approval, expiring on August 6, 2014. The incremental fair value of the warrant extension was negligible.
		f.	On December 20, 2012, options to purchase 20,000 shares of the Company were granted to a director at an exercise price of $6.00 per share (higher than the traded market price on the date of grant). The options vest in two equal annual installments, commencing January 1, 2013, and expire on December 19, 2022. The fair value of these options on the date of grant was $41,402, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 64.35%; risk-free interest rates of 1.01%; and expected term of 5.75 years.
		g.	On December 20, 2012, options to purchase 4,667 shares of the Companywere granted to an employee of the Subsidiary at an exercise price of $6.00 per share (higher than the traded market price on the date of grant). The options vest in two equal annual installments, commencing June 1, 2013, and expire on December 19, 2022. The fair value of these options on the date of grant was $9,660, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 64.35%; risk-free interest rates of 1.01%; and expected term of 5.75 years.
		h.	On April 14, 2013, options to purchase 100,800 shares of the Company's common stock were granted to an employee of the Subsidiary at an exercise price of $7.88 per share (equal to the traded market price on the date of grant). The options vest in 35 consecutive equal installments during a 3-year period commencing on May 31, 2013, and two installments of 1,400 shares of common stock each, that will vest on April 30, 2013 and April 14, 2016, and expire on April 14, 2023. The fair value of these options on the date of grant was $519,785, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 75.46%; risk-free interest rates of 0.92%; and expected term of 6 years  .
		i.	As to options granted to third parties, see notes 8d, 8e and 8f.
	The fair value of each option grant is estimated on the date of grant using the Black Scholes option-pricing model with the following assumptions:
			For options granted in
			the year ended August 31
			2013				2012
	Expected option life (years)			5.75-6				5.5-5.75
	Expected stock price volatility (%)			64.35-75.46				76.03
	Risk free interest rate (%)			0.92-1.01				0.83-1.0375
	Expected dividend yield (%)			0				0
	A summary of the status of the stock options granted to employees and directors as of August 31, 2013 and 2012, and changes during the years ended on those dates, is presented below:
			Year ended August 31,
			2013								2012
							Weighted								Weighted
			Number				average				Number				average
			of				exercise				of				exercise
			options				price				options				price
							$								$
	Options outstanding at
	beginning of year			932,116				3.72				834,117				3.84
	Changes during the year:
	Granted - at market price			100,800				7.88				244,334				4.08
	Granted - above market price			24,667				6				-
	Expired			-								(141,667	)			5.4
	Forfeited			-								(4,667	)			5.64
	Exercised			8,334				5.04				-
	Options outstanding at end
	of year			1,049,249				4.13				932,116				3.72
	Options exercisable at end
	of year			870,883								717,088
	Weighted average fair
	value of options granted
	during the year		$	4.55							$	2.65
	Costs incurred in respect of stock based compensation for employees and directors, for the years ended August 31, 2013 and 2012 were $562,966 and $200,866, respectively.
	The total intrinsic value of employees options exercised during the year ended August 31, 2013, was $17,584. No options were exercised during the year ended August 31, 2012.
	The following table presents summary information concerning the options granted to employees and directors outstanding as of August 31, 2013:
									Weighted
									Average				Weighted
	Range of								Remaining				average
	exercise				Number				Contractual				exercise				Aggregate
	prices				outstanding				Life				price				intrinsic value
	$								Years				$				$
	0.012					280,114				0.93				0.012				2,038,670
	4.08 to 6.48					668,335				7.05				5.28				1,340,874
	7.88					100,800				9.62				7.88				-
						1,049,249				5.66				4.13				3,379,544
	The following table presents summary information concerning the options granted to employees and directors exercisable as of August 31, 2013:
									Weighted
									Average				Weighted
	Range of								Remaining				average
	exercise				Number				Contractual				exercise				Aggregate
prices				exercisable				Life				price				intrinsic value
$								Years				$				$
0.012					280,114				0.93				0.012				2,038,670
4.08 to 6.48					578,169				6.74				5.43				1,075,120
7.88					12,600				9.62				7.88				-
					870,883				4.92				3.72				3,113,790
As of August 31, 2013, there were $475,485 of unrecognized compensation costs related to non-vested employees and directors, to be recorded over the next 32 months.
A summary of the status of the stock options granted to non-employees outstanding as of August 31, 2013, and changes during the years ended on this date, is presented below:
		Year ended August 31
		2013								2012
						Weighted								Weighted
		Number				average				Number				average
		of				exercise				of				exercise
		options				price				options				price
						$								$
Options outstanding at
beginning of year			144,856				6.66				82,356				7.2
Changes during the year:
Granted above market
price			-								62,500				6
Options outstanding at end
of year			144,856				6.66				144,856				6.66
Options exercisable at end
of year			109,969								88,689
The Company recorded stock compensation of $156,253 and $117,098 during the years ended August 31, 2013 and 2012, respectively, related to consulting services.
The following table presents summary information concerning the options granted to non-employees outstanding as of August 31, 2013:
								Weighted
								Average				Weighted
Range of								Remaining				Average
exercise				Number				Contractual				Exercise				Aggregate
prices				outstanding				Life				Price				intrinsic value
$								Years				$				$
4.08 to 6.00					111,520				3.79				5.93				151,785
9.12					33,336				4.33				9.12				-
					144,856				3.92				6.66				151,785
The following table presents summary information concerning the options granted to non-employee exercisable as of August 31, 2013:
								Weighted
								Average				Weighted
Range of								Remaining				average
exercise				Number				Contractual				exercise				Aggregate
prices				exercisable				Life				price				intrinsic value
$								Years				$				$
4.08 to 6.00					93,301				3.42				5.92				128,283
9.12					16,668				4.33				9.12				-
					109,969				3.55				6.4				128,283
As of August 31, 2013 there were $52,949 of unrecognized compensation costs related to non-vested non-employee options, to be recorded over the next 33 months.

ACCOUNTS_PAYABLE_AND_ACCRUED_E

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Aug. 31, 2013
ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]	'
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	'
	NOTE 11 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES:
		Year ended
		August 31,
		2013		2012
	Service providers	$	392,289	$	580,714
	Payroll and related expenses		58,652		16,459
		$	450,941	$	597,173

RESEARCH_AND_DEVELOPMENT_EXPEN

RESEARCH AND DEVELOPMENT EXPENSES, NET	12 Months Ended
	Aug. 31, 2013
RESEARCH AND DEVELOPMENT EXPENSES, NET [Abstract]	'
RESEARCH AND DEVELOPMENT EXPENSES, NET	'
	NOTE 12 - RESEARCH AND DEVELOPMENT EXPENSES, NET:
								Period from April
								12, 2002
								(inception)
		Year ended						through
		August 31,						August 31,
		2013			2012			2013
	Clinical trials	$	1,341,471		$	1,298,310		$	6,504,824
	Payroll and consulting fees		447,195			385,646			2,368,728
	Costs for registration of patents		106,687			110,811			558,297
	Compensation costs in respect of options granted to employees, directors and consultants		346,961			98,688			3,268,842
	Other		338,635			160,350			886,242
	Less - grants from the OCS and Bio Jerusalem Fund		(309,155	)		(372,959	)		(1,782,445	)
		$	2,271,794		$	1,680,845		$	11,804,488

GENERAL_AND_ADMINISTRATIVE_EXP

GENERAL AND ADMINISTRATIVE EXPENSES	12 Months Ended
	Aug. 31, 2013
GENERAL AND ADMINISTRATIVE EXPENSES [Abstract]	'
GENERAL AND ADMINISTRATIVE EXPENSES	'
	NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES
						Period from April
						12, 2002
						(inception)
		Year ended				through
		31-Aug				August 31,
		2013		2012		2013
	Compensation costs in respect of options granted to employees, directors and consultants	$	372,258	$	172,470	$	2,421,664
	Professional services		439,175		221,218		2,338,919
	Consulting fees		259,670		159,136		1,230,570
	Travel costs		127,196		71,529		673,126
	Write off of debt		-		-		275,000
	Business development		308,183		284,899		1,124,128
	Payroll and related expenses		230,191		144,101		983,399
	Insurance		43,399		22,375		162,320
	Other		252,057		127,436		984,550
		$	2,032,129	$	1,203,164	$	10,193,676

FINANCIAL_INCOME_AND_EXPENSES

FINANCIAL INCOME AND EXPENSES	12 Months Ended
	Aug. 31, 2013
FINANCIAL INCOME AND EXPENSES [Abstract]	'
FINANCIAL INCOME AND EXPENSES	'
	NOTE 14 - FINANCIAL INCOME AND EXPENSES
		a.	Financial income
			Year ended August 31
			2013		2012
	Gain on sale of marketable securities (note 3)		$	90,370	$	-
	Changes in fair value of warrants			44,699		-
	Income from interest			18,728		13,126
	Other			26,698		-
			$	180,495	$	13,126
		b.	Financial expenses
			Year ended August 31
			2013		2012
	Exchange of warrants		$	296,982	$	-
	Changes in fair value of warrants			-		142,704
	Exchange rate differences			2,804		35,067
	Bank commissions			13,660		14,952
	Other			-		6,400
			$	313,446	$	199,123

TAXES_ON_INCOME

TAXES ON INCOME	12 Months Ended
	Aug. 31, 2013
TAXES ON INCOME [Abstract]	'
TAXES ON INCOME	'
	NOTE 15 - TAXES ON INCOME:
	Taxes on income included in the consolidated statements of operations represent current taxes due to taxable income of the Company and its Subsidiary.
		a.	Corporate taxation in the U.S.
	The applicable corporate tax rate for the Company is 35%.
	As of August 31, 2013, the Company has an accumulated tax loss carryforward of approximately $5,605,237 (as of August 31, 2012, approximately $4,896,605). Under U.S. tax laws, carryforward tax losses expire 20 years after the year in which incurred. In the case of the Company, the net loss carryforward will expire in the years 2025 through 2032.
		b.	Corporate taxation in Israel:
	The Subsidiary is taxed in accordance with Israeli tax laws. The corporate tax rate applicable to 2012  and 2013 is 25%.
	On August 5, 2013, the Law for Change of National Priorities (Legislative Amendments for Achieving the Budgetary Goals for 2013-2014), 2013 was published in Reshumot (the Israeli government official gazette), enacting, among other things, the following raising the corporate tax rate beginning in 2014 and thereafter to 26.5% (instead of 25%).
	As of August 31, 2013, the Subsidiary has an accumulated tax loss carryforward of approximately $7,663,790 (as of August 31, 2012, approximately $5,905,361).
	Deferred income taxes:
			31-Aug
			2013			2012
	In respect of:
	Net operating loss carryforward			3,992,737			3,190,152
	Research and development expenses			338,908			18,008
	Less - Valuation allowance			(4,331,645	)		(3,208,160	)
	Net deferred tax assets			-,-			-,-
	Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a full valuation allowance.
		c.	Loss before taxes on income and income taxes included in the income statements of operations:
									Period from April
									12, 2002
									(inception)
			Year ended						through
			31-Aug						August 31,
			2013			2012			2013
	Loss before taxes on income:
	U.S.			1,185,831			599,067			9,626,374
	Outside U.S.			3,251,044			2,655,193			12,461,502
			$	4,436,874		$	3,254,260		$	22,087,875
	Income tax expenses (benefit):
	Current:
	U.S.			(12,960	)		(7,569	)		67,392
	Outside U.S.			(192,102	)		97,787			108,440
			$	(205,062	)	$	90,218		$	175,832
		d.	Reconciliation of the statutory tax benefit to effective tax expense
	Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates applicable to companies in the United States, and the actual tax expense:
									Period from April
									12, 2002
									(inception)
			Year ended						through
			31-Aug						August 31,
			2013			2012			2013
	Loss before income taxes as reported in
	the consolidated statement of operations		$	(4,436,874	)	$	(3,254,260	)	$	(22,087,875	)
	Statutory tax benefit			(1,522,906	)		(1,138,991	)		(7,700,757	)
	Increase (decrease) in income taxes
	resulting from:
	Change in the balance of the valuation
	allowance for deferred tax			902,509			516,749			3,573,334
	Disallowable deductions			374,059			120,156			2,617,605
	Increase in taxes resulting from
	different tax rates applicable to the
	Subsidiary			276,338			502,086			1,588,322
	Uncertain tax position			(205,062	)		90,218			23,210
	Taxes on income for the reported year		$	(205,062	)	$	90,218		$	35,714
		e.	Uncertainty in Income Taxes
	ASC No.740 "Income Taxes" requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. The Company recognizes interest and penalties related to its tax contingencies as income tax expense. As of August 31, 2013 and 2012, the Company recorded zero and $15,539, respectively, of penalties related to tax contingencies.
	The following table summarizes the activity of the Company unrecognized tax benefits:
			Year ended August 31
			2013			2012
	Balance at Beginning of Year		$	228,272		$	138,054
	Increase (decrease) in uncertain tax positions for the current year			(205,062	)		90,218
	Balance at End of Year		$	23,210		$	228,272
The decrease in uncertain tax positions for the year ended August 31, 2013, is a result of the expiration of the statute of limitations with respect to the 2008 tax year of the Subsidiary.
The Company does not expect unrecognized tax expenses to change significantly over the next 12 months.
The Company is  subject to  U.S. Federal income tax examinations for the tax years of 2008 through 2013.
The Subsidiary is subject to Israeli income tax examinations for the tax years of 2009 through 2013.

RELATED_PARTIES_TRANSACTIONS

RELATED PARTIES - TRANSACTIONS	12 Months Ended
	Aug. 31, 2013
RELATED PARTIES - TRANSACTIONS [Abstract]	'
RELATED PARTIES - TRANSACTIONS	'
	NOTE 16 - RELATED PARTIES - TRANSACTIONS:
		a.	During each of the fiscal years of 2013 and 2012 the Company paid to directors $39,361 and $30,000, respectively, for managerial services.
		b.	As to the agreements with Hadasit, see note 8a.
		c.	On July 1, 2008, the Subsidiary entered into a consulting agreement with KNRY Ltd. ("KNRY"), an Israeli company owned by Nadav Kidron, whereby Mr. Nadav Kidron, through KNRY, will provide services as President and Chief Executive Officer of both Oramed and the Subsidiary (the "Nadav Kidron Consulting Agreement").  Additionally, on July 1, 2008, the Subsidiary entered into a consulting agreement with KNRY whereby Dr. Miriam Kidron, through KNRY, will provide services as Chief Medical and Technology Officer of both Oramed and the Subsidiary (the "Miriam Kidron Consulting Agreement" and together with the Nadav Kidron Consulting Agreement, the "Consulting Agreements").  The Consulting Agreements replaced the employment agreements entered into between the Company and KNRY, dated as of August 1, 2007, pursuant to which Nadav Kidron and Miriam Kidron, respectively, provided services to the Company and the Subsidiary. The Consulting Agreements are both terminable by either party upon 60 days prior written notice.  The Consulting Agreements provide that KNRY (i) will be paid, under each of the Consulting Agreements, in NIS a gross amount of NIS 50,400 per month (as of August 31, 2012 the monthly payment in the Company's functional currency was $12,512) and (ii) will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements.
	On July 17, 2013, the Subsidiary entered into amendments to the Consulting Agreements with KNRY, according to which, Nadav Kidron's annual payment was set at $250,000, and in addition to such payment he will be granted the use of a company car and a one time cash bonus of $60,000, and Miriam Kidron's annual payment was set at $200,000, and in addition to such payment she was granted the use of a company car and a one time cash bonus of $20,000, both effective July 1, 2013.
		d.	As to options granted to related parties, see notes 10a and 10f.
		e.	Balances with related parties:
			31-Aug
			2013		2012
	Accounts Receivable - KNRY		$	1,377	$	404
	Accounts Receivable - Nadav Kidron*		$	3,153		-
	Accounts payable and accrued expenses - KNRY		$	64,355		-
		*  Down payment for travel expenses.
		f.	Expenses to related parties:
			31-Aug
			2013		2012
	KNRY		$	448,080	$	318,271

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Aug. 31, 2013
SUBSEQUENT EVENTS [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 17 - SUBSEQUENT EVENTS:
		a.	During  October  and November  2013, the Subsidiary sold in aggregate of 1,025,991 of the D.N.A shares for a total of $43,208. As of November 25, 2013, the Group owns approximately 10.6% of D.N.A's outstanding ordinary shares.
		b.	In November 2013, the Company issued 10,000 shares to an advisor. See also note 8h.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policy)	12 Months Ended
	Aug. 31, 2013
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
General	'
	a.	General
		1)	Incorporation and operations
			Oramed Pharmaceuticals Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd ("Hadasit") to acquire the provisional patent related to orally ingestible insulin pill to be used for the treatment of individuals with diabetes. In subsequent periods, the Company entered into additional development agreements with Hadasit, the most recent of which was signed on September 11, 2011, see also note 8a.
			On March 11, 2011, the Company was reincorporated from the State of Nevada to   the State of Delaware.
			On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term "Group" refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the "Subsidiary"), (together with the Company, "the Group").
			In March 2011, the Subsidiary sold shares of its investee company, Entera Bio Ltd ("Entera") to D.N.A Biomedical Solutions Ltd ("D.N.A"), remaining a 3% interest, which is accounted for as a cost method investment (amounting $1,027). In consideration for the shares sold to D.N.A, the Company received a promissory note issued by D.N.A in the principal amount of $450,000, with an annual interest rate of 0.45%, that was paid in full in November 2011, and 8,404,667 ordinary shares of D.N.A, see also note 3.
			As part of this agreement, the Subsidiary entered into a patent transfer agreement according to which, the Subsidiary assigned to Entera all of its right, title and interest in and to the patent application that it has licensed to Entera since August 2010.  Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera's net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. As of August 31, 2013, Entera had not yet realized any revenues and had not paid any royalties to the Subsidiary.
		2)	Development and liquidity risks
			The Company has been in the development stage since its formation and has not yet generated any revenues from its operations.
			The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with the ASC Topic 915 "Development Stage Entities" due to the fact that it has not generated any revenues from its operations.
	Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.
	Based on its current cash resources and commitments, and cash received in private and public offerings in the year ended August 31, 2013, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months and beyond, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.
		3)	Reverse stock split
	On January 10, 2013, the Company's Board of Directors approved a reverse stock split at a ratio of one-for-twelve, effective January 22, 2013, which decreased the number of common shares issued and outstanding as of January 23, 2013, from approximately 86.5 million shares to approximately 7.2 million shares and the number of authorized common shares from 200 million shares to approximately 16.7 million shares. All share and per share amounts included in the consolidated financial statements have been adjusted retroactively to reflect the effects of the reverse stock split.
Accounting principles	'
	b.	Accounting principles
		The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP").
Use of estimates in the preparation of financial statements	'
	c.	Use of estimates in the preparation of financial statements
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates.
	As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock based compensation, valuation and impairment of marketable securities and valuation of tax exposures.
Functional currency	'
	d.	Functional currency
	The currency of the primary economic environment in which the operations of the Group are conducted is the U.S. dollar ("$" or "dollar"). Therefore, the functional currency of the Group is the dollar.
	Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions - exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate.
Principles of consolidation	'
	e.	Principles of consolidation
	The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation.
Property and equipment	'
	f.	Property and equipment
	Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the assets.
	Annual rates of depreciation are as follows:
			%
	Computers and peripheral equipment			33
	Office furniture and equipment			15-33
	Leasehold improvements are amortized over the term of the lease which is shorter than the estimated useful life of the improvements.
Income taxes	'
	g.	Income taxes
	1. Deferred taxes
	Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets.
	Regarding the Subsidiary, the recognition is prohibited for deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities.
	Taxes that would apply in the event of disposal of investments in the subsidiary have not been taken into account in computing deferred taxes, as it is the Company's intention to hold this investment, not to realize it.
	2.  Uncertainty in income tax
	The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company's policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses.
Research and development	'
	h.	Research and development, net
	Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, costs of registered patents materials, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company's clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred.
	Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company out sources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.
	Grants received from the OCS and Bio-Jerusalem are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grants are deducted from the related research and development expenses as the costs are incurred and are presented in R&D expenses, net. See also notes 8(k) and 8(l).
Cash equivalents	'
	i.	Cash equivalents
	The Company considers all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.
Loss per common share	'
		j.	Loss per common share
	Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding and shares relating to receipts on account of shares in equity during the period. Outstanding stock options and  warrants have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options and warrants excluded from the calculation of diluted net loss was 2,343,972 for the year ended August 31, 2013 (1,892,180 for the year ended August 31, 2012). The computation of  basic and diluted net loss per common share was adjusted retroactively for all periods presented to reflect the Company's reverse stock split. See also note 1a(3).
Impairment in value of long-lived assets	'
	k.	Impairment in value of long-lived assets
	The Company reviews long-lived assets, to be held and used, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. In the event the sum of the expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment loss would be recognized, and the assets are written down to their estimated fair values
Stock based compensation	'
	l.	Stock based compensation
	Equity awards granted to employees are accounted for using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimated forfeitures based on historical experience and anticipated future conditions.
	The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. When stock options are granted as consideration for services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the consideration received or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.
Warrants issued as part of capital raisings that are classified as a liability	'
	m.	Warrants issued as part of capital raisings that are classified as a liability
	Warrants that entitle the holder to down-round protection (through ratchet and anti-dilution provisions) are classified as liabilities in the statement of financial position.
	The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net. See note 6.
Fair value measurement	'
	n.	Fair value measurement:
	Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:
		Level 1:	Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
		Level 2:	Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
		Level 3:	Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	As of August 31, 2013 the assets or liabilities measured at fair value comprise of available for sale securities (level 1).
	In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent.
	In order to secure the fulfillment of the Company's obligations under the derivatives agreements, the Company has placed a restricted deposit with the bank in an amount of $16,000.
	Available-for-sale securities are reported at fair value, with unrealized gains and losses, net of related tax recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.
	The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company's ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses.
Concentration of credit risks	'
	o.	Concentration of credit risks
	Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, deposit and short term investments which are deposited in major financial institutions. The Company is of the opinion that the credit risk in respect of these balances is remote.
Newly issued and recently adopted accounting pronouncements	'
	p.	Newly issued  and recently adopted accounting pronouncements:
		1	In June 2011, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update (ASU) 2011-05, an update to ASC No. 220, "Presentation of Comprehensive Income," which eliminates the option to present other comprehensive income and its components in the statement of shareholders' equity. The Company can elect to present the items of net income and other comprehensive income in a single continuous statement of comprehensive income or in two separate, but consecutive, statements. Under either method the statement would need to be presented with equal prominence as the other primary financial statements. The amended guidance, which must be applied retroactively, is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, with earlier adoption permitted. In December 2011, the FASB issued another update on the topic, which deferred the effective date pertaining only to the presentation of reclassification adjustments on the face of the financial statements. The Company adopted the pronouncement in the first quarter of fiscal year 2013.
		2	In February 2013, the FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU 2013-02"). This update requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, ASU 2013-02 requires presentation, either on the face of the income statement or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by respective line items of net income, but only if the amounts reclassified are required to be reclassified in their entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about these amounts. The amendments in ASU 2013-02 will be effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. The accounting update will be applicable to the Company beginning in the first quarter of fiscal year 2014. The Company does not expect the adoption of ASU 2013-02 to have a material effect on the consolidated financial statement presentation.
		3	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (ASU 2013-11). This update requires an entity to present  in the financial statements  an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The assessment of whether a deferred tax asset is available is based on the unrecognized tax benefit and deferred tax asset that exist at the reporting date and should be made presuming disallowance of the tax position at the reporting date. The amendments in ASU 2013-11 will be effective prospectively for annual reporting periods beginning after December 15, 2013, and interim periods within those annual periods. The accounting update will be applicable to the Company beginning in the first quarter of fiscal year 2015.  The Company does not expect the adoption of ASU 2013-11 to have a material effect on the consolidated financial statement presentation.

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Aug. 31, 2013
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Schedule of Annual Depreciation Rates	'
		%
	Computers and peripheral equipment		33
	Office furniture and equipment		15-33

SHORT_TERM_INVESTMENTS_Tables

SHORT TERM INVESTMENTS (Tables)	12 Months Ended
	Aug. 31, 2013
SHORT TERM INVESTMENTS [Abstract]	'
Schedule of Short Term Investments	'
	31-Aug
		2013				2012
		Annual interest rate		Amount		Annual		Amount
						interest rate
	Dollar deposits		0.6-1.06%	$	5,111,914		0.85%	$	260,371
	NIS deposits		1.93%		134,713		1.93-1.97%		194,010
				$	5,246,627			$	454,381

MARKETABLE_SECURITIES_Tables

MARKETABLE SECURITIES (Tables)	12 Months Ended
	Aug. 31, 2013
MARKETABLE SECURITIES [Abstract]	'
Schedule of Marketable Securities Carried at Fair Value	'
		Level 1
	Marketable securities:
	31-Aug-13	$	956,376
	31-Aug-12	$	200,311
Schedule of Financial Assets Measured Using Unobservable Inputs	'
		31-Aug
		2013			2012
	Carrying value at the beginning of the period	$	-		$	384,565
	Additions		628,630			-
	Reclassification to level 1		(628,630	)		(384,565	)
	Carrying value at the end of the period	$	-		$	-

PREPAID_EXPENSES_AND_OTHER_CUR1

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Aug. 31, 2013
PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]	'
Schedule of Prepaid Expenses and Other Current Assets	'
		31-Aug
		2013		2012
	Tax Authorities	$	59,898	$	53,341
	Prepaid expenses and other  receivables		30,205		36,657
		$	90,103	$	89,998

PROPERTY_AND_EQUIPMENT_NET_Tab

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Aug. 31, 2013
PROPERTY AND EQUIPMENT, Net [Abstract]	'
Schedule of Property and Equipment	'
		31-Aug
		2013		2012
	Cost:
	Leasehold improvements	$	76,029	$	76,029
	Office furniture and equipment		19,941		19,941
	Computers and peripheral equipment		34,301		29,642
			130,271		125,612
	Less - accumulated depreciation and amortization		124,503		120,844
		$	5,768	$	4,768

WARRANTS_Tables

WARRANTS (Tables)	12 Months Ended
	Aug. 31, 2013
WARRANTS [Abstract]	'
Schedule of Warrants Carried at Fair Value	'
		Fair value measurements at reporting
		date using
		Level 3			Total
	Warrants -
	31-Aug-13	$	-		$	-
	31-Aug-12	$	637,182		$	637,182
Schedule of Liabilities Measured at Fair Value Using Significant Unobservable Inputs	'
		Year ended August 31,			Year ended August 31,
		2013			2012
	Carrying value at the beginning of the period	$	637,182		$	-
	Additional warrant liabilities granted		28,344			494,478
	Changes in fair value		(44,699	)		142,704
	Exchange of warrants		(620,827	)		-
	Carrying value at the end of the period	$	-		$	637,182

STOCKBASED_COMPENSATION_Tables

STOCKBASED COMPENSATION (Tables)	12 Months Ended
	Aug. 31, 2013
STOCK BASED COMPENSATION [Abstract]	'
Schedule of Fair Value Assumptions	'
		For options granted in
		the year ended August 31
		2013				2012
	Expected option life (years)		5.75-6				5.5-5.75
	Expected stock price volatility (%)		64.35-75.46				76.03
	Risk free interest rate (%)		0.92-1.01				0.83-1.0375
	Expected dividend yield (%)		0				0
Schedule of Stock Option Activity for Employees	'
		Year ended August 31,
		2013								2012
						Weighted								Weighted
		Number				average				Number				average
		of				exercise				of				exercise
		options				price				options				price
						$								$
	Options outstanding at
	beginning of year		932,116				3.72				834,117				3.84
	Changes during the year:
	Granted - at market price		100,800				7.88				244,334				4.08
	Granted - above market price		24,667				6				-
	Expired		-								(141,667	)			5.4
	Forfeited		-								(4,667	)			5.64
	Exercised		8,334				5.04				-
	Options outstanding at end
	of year		1,049,249				4.13				932,116				3.72
	Options exercisable at end
	of year		870,883								717,088
	Weighted average fair
	value of options granted
	during the year	$	4.55							$	2.65
Summary of Information for Options Granted and Exercisable for Employees	'
	The following table presents summary information concerning the options granted to employees and directors outstanding as of August 31, 2013:
								Weighted
								Average				Weighted
	Range of							Remaining				average
	exercise			Number				Contractual				exercise				Aggregate
	prices			outstanding				Life				price				intrinsic value
	$							Years				$				$
	0.012				280,114				0.93				0.012				2,038,670
	4.08 to 6.48				668,335				7.05				5.28				1,340,874
	7.88				100,800				9.62				7.88				-
					1,049,249				5.66				4.13				3,379,544
	The following table presents summary information concerning the options granted to employees and directors exercisable as of August 31, 2013:
								Weighted
								Average				Weighted
	Range of							Remaining				average
	exercise			Number				Contractual				exercise				Aggregate
	prices			exercisable				Life				price				intrinsic value
	$							Years				$				$
	0.012				280,114				0.93				0.012				2,038,670
	4.08 to 6.48				578,169				6.74				5.43				1,075,120
	7.88				12,600				9.62				7.88				-
					870,883				4.92				3.72				3,113,790
Schedule of Stock Option Activity for Non-Employees	'
		Year ended August 31
		2013								2012
						Weighted								Weighted
		Number				average				Number				average
		of				exercise				of				exercise
		options				price				options				price
						$								$
	Options outstanding at
	beginning of year		144,856				6.66				82,356				7.2
	Changes during the year:
	Granted above market
	price		-								62,500				6
	Options outstanding at end
	of year		144,856				6.66				144,856				6.66
	Options exercisable at end
	of year		109,969								88,689
Summary of Information for Options Granted and Exercisable for Non-Employees	'
	The following table presents summary information concerning the options granted to non-employees outstanding as of August 31, 2013:
								Weighted
								Average				Weighted
	Range of							Remaining				Average
	exercise			Number				Contractual				Exercise				Aggregate
	prices			outstanding				Life				Price				intrinsic value
	$							Years				$				$
	4.08 to 6.00				111,520				3.79				5.93				151,785
	9.12				33,336				4.33				9.12				-
					144,856				3.92				6.66				151,785
	The following table presents summary information concerning the options granted to non-employee exercisable as of August 31, 2013:
								Weighted
								Average				Weighted
	Range of							Remaining				average
	exercise			Number				Contractual				exercise				Aggregate
	prices			exercisable				Life				price				intrinsic value
	$							Years				$				$
	4.08 to 6.00				93,301				3.42				5.92				128,283
	9.12				16,668				4.33				9.12				-
					109,969				3.55				6.4				128,283

ACCOUNTS_PAYABLE_AND_ACCRUED_E1

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Aug. 31, 2013
ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]	'
Schedule of Accounts Payable and Accrued Expenses	'
		Year ended
		August 31,
		2013		2012
	Service providers	$	392,289	$	580,714
	Payroll and related expenses		58,652		16,459
		$	450,941	$	597,173

RESEARCH_AND_DEVELOPMENT_EXPEN1

RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)	12 Months Ended
	Aug. 31, 2013
RESEARCH AND DEVELOPMENT EXPENSES, NET [Abstract]	'
Schedule of Research and Development Expenses	'
								Period from April
								12, 2002
								(inception)
		Year ended						through
		August 31,						August 31,
		2013			2012			2013
	Clinical trials	$	1,341,471		$	1,298,310		$	6,504,824
	Payroll and consulting fees		447,195			385,646			2,368,728
	Costs for registration of patents		106,687			110,811			558,297
	Compensation costs in respect of options granted to employees, directors and consultants		346,961			98,688			3,268,842
	Other		338,635			160,350			886,242
	Less - grants from the OCS and Bio Jerusalem Fund		(309,155	)		(372,959	)		(1,782,445	)
		$	2,271,794		$	1,680,845		$	11,804,488

GENERAL_AND_ADMINISTRATIVE_EXP1

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)	12 Months Ended
	Aug. 31, 2013
GENERAL AND ADMINISTRATIVE EXPENSES [Abstract]	'
Schedule of General and Administrative Expenses	'
						Period from April
							12, 2002
							(inception)
		Year ended					through
		31-Aug					August 31,
		2013		2012			2013
	Compensation costs in respect of options granted to employees, directors and consultants	$	372,258	$	172,470		$	2,421,664
	Professional services		439,175		221,218			2,338,919
	Consulting fees		259,670		159,136			1,230,570
	Travel costs		127,196		71,529			673,126
	Write off of debt		-		-			275,000
	Business development		308,183		284,899			1,124,128
	Payroll and related expenses		230,191		144,101			983,399
	Insurance		43,399		22,375			162,320
	Other		252,057		127,436			984,550
		$	2,032,129	$	1,203,164		$	10,193,676

FINANCIAL_INCOME_AND_EXPENSES_

FINANCIAL INCOME AND EXPENSES (Tables)	12 Months Ended
	Aug. 31, 2013
FINANCIAL INCOME AND EXPENSES [Abstract]	'
Schedule of Financial Income	'
		Year ended August 31
		2013		2012
	Gain on sale of marketable securities (note 3)	$	90,370	$	-
	Changes in fair value of warrants		44,699		-
	Income from interest		18,728		13,126
	Other		26,698		-
		$	180,495	$	13,126
Schedule of Financial Expenses	'
		Year ended August 31
		2013		2012
	Exchange of warrants	$	296,982	$	-
	Changes in fair value of warrants		-		142,704
	Exchange rate differences		2,804		35,067
	Bank commissions		13,660		14,952
	Other		-		6,400
		$	313,446	$	199,123

TAXES_ON_INCOME_Tables

TAXES ON INCOME (Tables)	12 Months Ended
	Aug. 31, 2013
TAXES ON INCOME [Abstract]	'
Schedule of Deferred Income Taxes	'
		31-Aug
		2013			2012
	In respect of:
	Net operating loss carryforward		3,992,737			3,190,152
	Research and development expenses		338,908			18,008
	Less - Valuation allowance		(4,331,645	)		(3,208,160	)
	Net deferred tax assets		-,-			-,-
Schedule of Income Taxes Included in the Income Statements	'
							Period from April
								12, 2002
								(inception)
		Year ended						through
		31-Aug						August 31,
		2013			2012			2013
	Loss before taxes on income:
	U.S.		1,185,831			599,067			9,626,374
	Outside U.S.		3,251,044			2,655,193			12,461,502
		$	4,436,874		$	3,254,260		$	22,087,875
	Income tax expenses (benefit):
	Current:
	U.S.		(12,960	)		(7,569	)		67,392
	Outside U.S.		(192,102	)		97,787			108,440
		$	(205,062	)	$	90,218		$	175,832
Schedule of Reconciliation of Income Taxes	'
								Period from April
								12, 2002
								(inception)
		Year ended						through
		31-Aug						August 31,
		2013			2012			2013
	Loss before income taxes as reported in
	the consolidated statement of operations	$	(4,436,874	)	$	(3,254,260	)	$	(22,087,875	)
	Statutory tax benefit		(1,522,906	)		(1,138,991	)		(7,700,757	)
	Increase (decrease) in income taxes
	resulting from:
	Change in the balance of the valuation
	allowance for deferred tax		902,509			516,749			3,573,334
	Disallowable deductions		374,059			120,156			2,617,605
	Increase in taxes resulting from
	different tax rates applicable to the
	Subsidiary		276,338			502,086			1,588,322
	Uncertain tax position		(205,062	)		90,218			23,210
	Taxes on income for the reported year	$	(205,062	)	$	90,218		$	35,714
Schedule of Unrecognized Tax Benefits Activity	'
		Year ended August 31
		2013			2012
	Balance at Beginning of Year	$	228,272		$	138,054
	Increase (decrease) in uncertain tax positions for the current year		(205,062	)		90,218
	Balance at End of Year	$	23,210		$	228,272

RELATED_PARTIES_TRANSACTIONS_T

RELATED PARTIES - TRANSACTIONS (Tables)	12 Months Ended
	Aug. 31, 2013
RELATED PARTIES - TRANSACTIONS [Abstract]	'
Schedule of Balances with Related Parties	'
		31-Aug
		2013		2012
	Accounts Receivable - KNRY	$	1,377	$	404
	Accounts Receivable - Nadav Kidron*	$	3,153		-
	Accounts payable and accrued expenses - KNRY	$	64,355		-
Schedule of Related Party Expenses	'
		31-Aug
		2013		2012
	KNRY	$	448,080	$	318,271

SIGNIFICANT_ACCOUNTING_POLICIE3

SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended		137 Months Ended	12 Months Ended					1 Months Ended	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013	Aug. 31, 2013	Aug. 31, 2013	Oct. 31, 2012	Aug. 31, 2013	Aug. 31, 2013
	USD ($)	USD ($)	USD ($)	Stock Options And Warrants [Member]	Stock Options And Warrants [Member]	Computers and Peripheral Equipment [Member]	Office Furniture and Equipment [Member]	Office Furniture and Equipment [Member]	D.N.A. Biomedical Solutions Ltd. [Member]	D.N.A. Biomedical Solutions Ltd. [Member]	D.N.A. Biomedical Solutions Ltd. [Member]
							Minimum [Member]	Maximum [Member]	USD ($)	USD ($)	ILS
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Reverse stock split ratio	12	'	12	'	'	'	'	'	'	'	'
Common stock, shares issued, prior to reverse stock split	86,500,000	'	86,500,000	'	'	'	'	'	'	'	'
Common stock, shares outstanding, prior to reverse stock split	86,500,000	'	86,500,000	'	'	'	'	'	'	'	'
Common stock, shares authorized, prior to reverse stock split	200,000,000	'	200,000,000	'	'	'	'	'	'	'	'
Common stock, shares issued	$95,238	$80,075	$95,238	'	'	'	'	'	'	'	'
Common stock, shares outstanding	7,937,872	6,674,068	7,937,872	'	'	'	'	'	'	'	'
Common stock, shares authorized	16,666,667	16,666,667	16,666,667	'	'	'	'	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Cost method investment	'	'	'	'	'	'	'	'	'	1,027	'
Proceeds from issuance of common stock and warrants - net of issuance expenses	5,714,918	3,488,942	20,859,553	'	'	'	'	'	628,630	114,130	420,000
Percent shares owned by investor	'	'	'	'	'	'	'	'	'	3.00%	3.00%
Percentage of D.N.A. shares owned	'	'	'	'	'	'	'	'	'	11.10%	11.10%
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Depreciation rate	'	'	'	'	'	33.00%	15.00%	33.00%	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Antidilutive securities	'	'	'	2,343,972	1,892,180	'	'	'	'	'	'
Fair value measurement	'	'	'	'	'	'	'	'	'	'	'
Restricted deposit	$16,000	'	$16,000	'	'	'	'	'	'	'	'

SHORT_TERM_INVESTMENTS_Details

SHORT TERM INVESTMENTS (Details) (USD $)	Aug. 31, 2013	Aug. 31, 2012
Short Term Investments [Line Items]	'	'
Amount	$5,246,627	$454,831
Dollars deposits [Member]	'	'
Short Term Investments [Line Items]	'	'
Interest rate	'	0.85%
Amount	5,111,914	260,371
Dollars deposits [Member] | Minimum [Member]	'	'
Short Term Investments [Line Items]	'	'
Interest rate	0.60%	'
Dollars deposits [Member] | Maximum [Member]	'	'
Short Term Investments [Line Items]	'	'
Interest rate	1.06%	'
NIS deposits [Member]	'	'
Short Term Investments [Line Items]	'	'
Interest rate	1.93%	'
Amount	$134,713	$194,010
NIS deposits [Member] | Minimum [Member]	'	'
Short Term Investments [Line Items]	'	'
Interest rate	'	1.93%
NIS deposits [Member] | Maximum [Member]	'	'
Short Term Investments [Line Items]	'	'
Interest rate	'	1.97%

MARKETABLE_SECURITIES_Details

MARKETABLE SECURITIES (Details)	12 Months Ended		0 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Mar. 05, 2013	Mar. 05, 2013	Feb. 14, 2013	Feb. 14, 2013	Aug. 31, 2013	Oct. 31, 2012	Aug. 31, 2013	Aug. 31, 2012
	USD ($)	USD ($)	D.N.A. Biomedical Solutions Ltd. [Member]	D.N.A. Biomedical Solutions Ltd. [Member]	D.N.A. Biomedical Solutions Ltd. [Member]	D.N.A. Biomedical Solutions Ltd. [Member]	D.N.A. Biomedical Solutions Ltd. [Member]	D.N.A. Biomedical Solutions Ltd. [Member]	Level 1 [Member]	Level 1 [Member]
			USD ($)	ILS	USD ($)	ILS			USD ($)	USD ($)
MARKETABLE SECURITIES [Abstract]	'	'	'	'	'	'	'	'	'	'
Carrying value at the beginning of the period	'	$384,565	'	'	'	'	'	'	'	'
Additions - see note 9d	628,630	'	'	'	'	'	'	'	'	'
Changes in fair value	328,950	'	'	'	'	'	'	'	'	'
Reclassification adjustment for gains included in net loss	-52,343	'	'	'	'	'	'	'	'	'
Reclassification to level 1	-905,237	-384,565	'	'	'	'	'	'	'	'
Carrying value at the end of the period	'	'	'	'	'	'	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'	'	'	'	'	'
Marketable securities	'	'	'	'	'	'	'	'	956,376	200,311
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'	'
Option to purchase shares of D.N.A.	'	'	'	'	'	'	'	21,637,611	'	'
Shares of stock sold	'	'	1,750,000	1,750,000	3,500,000	3,500,000	'	'	'	'
Value of shares of stock sold	'	'	$112,540	420,000	$114,130	420,000	'	'	'	'
Percentage of D.N.A. shares owned	'	'	'	'	'	'	11.10%	'	'	'

PREPAID_EXPENSES_AND_OTHER_CUR2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) (USD $)	Aug. 31, 2013	Aug. 31, 2012
PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]	'	'
Tax Authorities	$59,898	$53,341
Prepaid expenses and other receivables	30,205	36,657
Total prepaid expenses and other current assets	$90,103	$89,998

PROPERTY_AND_EQUIPMENT_NET_Det

PROPERTY AND EQUIPMENT, NET (Details) (USD $)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'
Cost	$130,271	$125,612	$130,271
Less - accumulated depreciation and amortization	124,503	120,844	124,503
Property and equipment, net	5,768	4,768	5,768
Depreciation expenses	5,379	14,737	126,223
Leasehold Improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Cost	76,029	76,029	76,029
Office Furniture and Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Cost	19,941	19,941	19,941
Computers and Peripheral Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Cost	$34,301	$29,642	$34,301

WARRANTS_Details

WARRANTS (Details) (USD $)

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Aug. 31, 2013

Aug. 31, 2012

Oct. 31, 2012

Aug. 31, 2012

Nov. 30, 2012

Aug. 31, 2012

Jan. 31, 2011

Nov. 30, 2012

Nov. 29, 2012

Nov. 29, 2012

Nov. 30, 2012

Aug. 31, 2013

Aug. 31, 2012

2011 Warrants [Member]

2011 Warrants [Member]

Three Warrants [Member]

Three Warrants [Member]

Three Warrants [Member]

Three Warrants [Member]

Three Warrants [Member]

New Warrant [Member]

Kidron Option [Member]

Level 3 [Member]

Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants

'

$637,182

'

'

'

'

'

'

'

'

'

'

$637,182

Warrants [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants granted

'

'

'

'

16,892

112,613

182,292

137,311

'

137,311

'

'

'

Warrant term

'

'

'

'

'5 years

'5 years

'5 years

'

'

'4 years

'

'

'

Number of shares authorized by warrant

'

'

290,459

246,341

'

'

'

'

'

'

112,690

'

'

Exercise price per share

'

'

3.7656

4.44

6

6

6

6

3.7656

7.2

'

'

'

Warrants (notes 6)

'

637,182

'

'

'

'

'

'

'

145,173

168,220

'

'

Expected dividend yield (%)

0.00%

0.00%

'

'

'

'

'

'

'

0.00%

'

'

'

Expected option life (years)

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

Expected volatility

'

'

'

'

'

'

'

'

'

62.29%

'

'

'

Risk-free interest rate

'

'

'

'

'

'

'

'

'

0.57%

'

'

'

Financial expense

'

'

'

'

'

'

'

296,982

'

'

'

'

'

Carrying value at the beginning of the period

637,182

'

'

'

'

'

'

'

'

'

'

'

'

Additional warrant liabilities granted

28,344

494,478

'

'

'

'

'

'

'

'

'

'

'

Changes in fair value

-44,699

142,704

'

'

'

'

'

'

'

'

'

'

'

Exchange of warrants

-620,827

'

'

'

'

'

'

'

'

'

'

'

'

Carrying value at the end of the period

'

$637,182

'

'

'

'

'

'

'

'

'

'

'

EMPLOYEES_RIGHTS_UPON_RETIREME1

EMPLOYEES RIGHTS UPON RETIREMENT (Details) (USD $)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
EMPLOYEE RIGHTS UPON TERMINATION [Abstract]	'	'
Severance pay insurance deposits	$2,090	$3,620
Severance pay expenses	23,331	5,615
Severance pay expenses in respect of Contribution Plan	12,592	7,089
Severance pay expected deposit	25,480	'
Severance pay expected liability to Contribution Plan	$22,835	'

COMMITMENTS_Details

COMMITMENTS (Details)

12 Months Ended

137 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

137 Months Ended

12 Months Ended

137 Months Ended

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2011

Aug. 31, 2013

Aug. 31, 2011

Aug. 31, 2013

Aug. 31, 2012

Nov. 04, 2013

Aug. 31, 2013

Apr. 15, 2013

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2013

USD ($)

USD ($)

USD ($)

Vehicles Lease [Member]

Vehicles Lease [Member]

Office Facilities Lease [Member]

Office Facilities Lease [Member]

Office Facilities Lease [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Hadasit [Member]

Consultant [Member]

Consultant [Member]

Third Party [Member]

Third Party [Member]

Related Party [Member]

Related Party [Member]

Advisor [Member]

Advisor [Member]

Advisor [Member]

Clinical Research Organization [Member]

Master Service Agreement [Member]

Bio-Jerusalem [Member]

Bio-Jerusalem [Member]

Chief Scientist Office [Member]

Chief Scientist Office [Member]

Chief Scientist Office [Member]

Chief Scientist Office [Member]

Chief Scientist Office [Member]

USD ($)

USD ($)

USD ($)

USD ($)

ILS

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Minimum [Member]

Maximum [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments for consulting services

'

'

'

'

'

'

'

'

'

'

'

'

$200,000

'

'

'

'

'

'

'

'

'

$332,702

$102,280

'

'

'

'

'

'

'

Professional services

439,175

221,218

2,338,919

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

89,830

30,684

'

'

'

'

'

'

'

Commitments for consulting service, monthly fixed fee

'

'

'

'

'

'

'

'

'

'

'

'

'

8,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares to be issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

10,000

5,000

15,000

'

'

'

'

'

'

'

'

'

Royalty percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

4.00%

4.00%

'

'

'

3.00%

3.50%

Royalty percentage, maximum percentage of grants received

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

100.00%

100.00%

'

100.00%

'

'

Capital raise amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

65,053

65,053

1,659,338

'

1,659,338

'

'

Number of shares authorized by warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

20,834

'

'

32,000

'

62,500

'

'

'

'

'

'

'

'

'

'

'

'

Warrant term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

6

'

'

6

'

6

'

'

'

'

'

'

'

'

'

'

'

'

Warrants vesting, number of installments

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

12

'

12

'

'

3

'

'

'

'

'

'

'

'

'

Fair value of options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

62,185

'

9,169

5,057

164,752

121,304

'

34,900

'

'

'

'

'

'

'

'

'

'

Expected dividend yield (%)

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

Expected volatility

'

'

'

'

'

'

'

'

'

'

'

'

'

76.87%

78.65%

76.41%

77.39%

76.16%

76.82%

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

2.33%

3.62%

0.79%

1.55%

0.77%

0.81%

'

'

'

'

'

'

'

'

'

'

'

'

Expected option life (years)

'

'

'

'

'

'

'

'

'5 years 9 months

'5 years 6 months

'6 years

'5 years 9 months

'

'7 years 5 months 16 days

'10 years

'2 years 10 months 24 days

'5 years

'4 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

Research and development expenses

2,271,794

1,680,845

11,804,488

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,319

65,053

296,836

372,959

1,717,392

'

'

Long-term Purchase Commitment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating lease term

'

'

'

'3 years

'

'36 months

'57 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease expenses

'

'

'

29,603

29,543

13,116

9,132

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future lease payments due in 2014

'

'

'

24,603

'

24,641

'

89,052

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future lease payments due in 2015

'

'

'

17,615

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future lease payments due in 2016

'

'

'

7,340

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deposit for lease agreement

'

'

'

$1,959

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details)

1 Months Ended

12 Months Ended

65 Months Ended

137 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

12 Months Ended

Jul. 30, 2013

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2011

Aug. 31, 2010

Aug. 31, 2009

Aug. 31, 2008

Aug. 31, 2007

Aug. 31, 2013

15-May-12

Mar. 14, 2012

Dec. 12, 2011

Jul. 05, 2012

Mar. 14, 2012

Jul. 30, 2013

Aug. 31, 2012

Nov. 30, 2012

Jul. 30, 2013

Aug. 31, 2012

Aug. 31, 2012

Nov. 30, 2012

Nov. 30, 2012

Nov. 30, 2012

Oct. 31, 2012

Aug. 31, 2013

Aug. 31, 2013

Aug. 31, 2011

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Advisor [Member]

Advisor [Member]

Advisor [Member]

Advisor Two [Member]

Advisor Two [Member]

Advisor Two [Member]

Securities Purchase Agreement [Member]

Securities Purchase Agreement [Member]

Securities Purchase Agreement Two [Member]

Securities Purchase Agreement Two [Member]

Leading Investor [Member]

Leading Investor [Member]

Other Individual [Member]

Directors [Member]

D.N.A. Biomedical Solutions Ltd. [Member]

D.N.A. Biomedical Solutions Ltd. [Member]

D.N.A. Biomedical Solutions Ltd. [Member]

D.N.A. Biomedical Solutions Ltd. [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

ILS

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Securities Purchase Agreements, number of units

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

801,942

335,524

658,144

5,652

225,226

33,784

'

'

'

'

'

'

Number of shares to be sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,625

'

'

1,127

12,745

199,172

'

'

'

Number of shares authorized by warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,826

'

'

564

6,373

'

'

'

'

Securities Purchase Agreements, purchase price per unit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.44

$4.44

$7

$4.44

'

'

'

'

'

'

'

'

Proceeds from issuance of shares

'

$5,714,918

$3,488,942

'

'

'

'

'

$20,859,553

'

'

'

'

'

'

$3,560,192

$1,464,425

$4,238,889

$25,093

'

'

'

'

$628,630

$114,130

420,000

'

Securities Purchase Agreements, number of shares per unit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

1

'

1

'

'

'

'

'

'

'

'

Securities Purchase Agreements, number of warrants per unit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

1

'

1

'

'

'

'

'

'

'

'

Securities Purchase Agreements, number of shares per warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.5

0.5

'

0.5

'

'

'

'

'

'

'

'

Warrant term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'

'5 years

'

'

'

'

'

'

'

'5 years

Exercise price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

6

'

6

'

'

'

'

'

'

'

'

Stock issued for services, shares

12,042

'

'

'

'

'

'

'

'

6,917

6,917

6,917

4,167

4,167

16,667

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued for services

86,221

'

107,860

227,569

249,850

152,928

116,110

98,750

'

24,900

26,560

24,900

16,000

15,500

123,336

'

'

'

'

'

'

'

'

'

'

'

'

Finders fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$255,246

$71,250

'

'

$12,885

'

'

'

'

'

Option to purchase shares of D.N.A.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,637,611

'

'

'

Percent shares owned by investor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

5.00%

'

'

'

3.00%

3.00%

'

STOCKBASED_COMPENSATION_Narrat

STOCKBASED COMPENSATION (Narrative) (Details) (USD $)

1 Months Ended

12 Months Ended

65 Months Ended

137 Months Ended

12 Months Ended

12 Months Ended

Jul. 30, 2013

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2011

Aug. 31, 2010

Aug. 31, 2009

Aug. 31, 2008

Aug. 31, 2007

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2013

Aug. 31, 2012

Nov. 30, 2012

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2012

Aug. 31, 2013

Nadav Kidron and Miriam Kidron [Member]

Directors [Member]

Directors [Member]

Directors [Member]

Subsidiary Employee One [Member]

Subsidiary Employee One [Member]

Subsidiary Employee Two [Member]

Subsidiary Employee Two [Member]

Miriam Kidron [Member]

2008 Stock Option Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares reserved for grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

Stock issued for services, shares

12,042

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued for services

$86,221

'

$107,860

$227,569

$249,850

$152,928

$116,110

$98,750

'

'

'

'

'

'

'

'

'

'

'

Granted - at market price

'

'

'

'

'

'

'

'

'

144,000

20,000

43,334

'

4,667

50,750

100,800

6,250

280,114

'

Granted - at market price

'

'

'

'

'

'

'

'

'

$4.08

$6

$4.08

'

$6

$4.08

$7.88

$4.08

'

'

Options to purchase, number of shares

'

'

'

'

'

'

'

'

'

'

'

'

6,373

'

'

'

'

'

'

Proceeds from issuance of shares

'

5,714,918

3,488,942

'

'

'

'

'

20,859,553

'

'

'

'

'

'

'

'

'

'

Options vesting, number of installments

'

'

'

'

'

'

'

'

'

17

2

2

'

2

29

35

3

'

'

Options vested

'

'

'

'

'

'

'

'

'

42,000

'

'

'

'

'

'

'

'

'

Shares per installment

'

'

'

'

'

'

'

'

'

6,000

'

'

'

'

'

1,400

'

'

'

Fair value of options granted

'

'

'

'

'

'

'

'

'

373,565

41,402

114,694

'

9,660

134,324

519,785

16,780

'

'

Expected dividend yield (%)

'

0.00%

0.00%

'

'

'

'

'

'

0.00%

0.00%

0.00%

'

0.00%

0.00%

0.00%

0.00%

'

'

Expected volatility

'

'

'

'

'

'

'

'

'

76.03%

64.35%

76.03%

'

64.35%

76.03%

75.46%

76.03%

'

'

Expected stock price volatility (%), minimum

'

64.35%

76.03%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected stock price volatility (%), maximum

'

75.46%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate

'

'

'

'

'

'

'

'

'

0.83%

1.01%

1.04%

'

1.01%

1.04%

0.92%

0.94%

'

'

Risk-free interest rate (%), minimum

'

0.92%

0.83%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate (%), maximum

'

1.01%

1.04%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected option life (years)

'

'

'

'

'

'

'

'

'

'5 years 6 months

'5 years 9 months

'5 years 9 months

'

'5 years 9 months

'5 years 9 months

'6 years

'6 years

'

'

Intrinsic value of options exercised

'

$17,584

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

STOCKBASED_COMPENSATION_Schedu

STOCKBASED COMPENSATION (Schedule of Fair Value Assumptions) (Details)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected stock price volatility (%), minimum	64.35%	76.03%
Expected stock price volatility (%), maximum	75.46%	'
Risk-free interest rate (%), minimum	0.92%	0.83%
Risk-free interest rate (%), maximum	1.01%	1.04%
Expected dividend yield (%)	0.00%	0.00%
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected option life (years)	'5 years 9 months	'5 years 6 months
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected option life (years)	'6 years	'5 years 9 months

STOCKBASED_COMPENSATION_Schedu1

STOCKBASED COMPENSATION (Schedule of Stock Option Activity) (Details) (USD $)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
Weighted average exercise price	'	'	'
Stockbased compensation expense	$372,258	$172,470	$2,421,664
Employees [Member]	'	'	'
Number of options	'	'	'
Options outstanding at beginning of year	932,116	834,117	'
Granted - at market price	100,800	244,334	'
Granted - above market price	24,667	'	'
Expired	'	-141,667	'
Forfeited	'	-4,667	'
Exercised	-8,334	'	'
Options outstanding at end of year	1,049,249	932,116	1,049,249
Options exercisable at end of year	870,833	717,088	870,833
Weighted average fair value of options granted during the year	$4.55	$2.65	'
Weighted average exercise price	'	'	'
Options outstanding at beginning of year	$3.72	$3.84	'
Granted - at market price	$7.88	$4.08	'
Granted - above market price	$6	'	'
Expired	'	$5.40	'
Forfeited	'	$5.64	'
Exercised	$5.04	'	'
Options outstanding at end of year	$4.13	$3.72	$4.13
Stockbased compensation expense	562,966	200,866	'
Unrecognized compensation expense	475,485	'	475,485
Period over which compensation expense will be recognized	'32 months	'	'
Nonemployees [Member]	'	'	'
Number of options	'	'	'
Options outstanding at beginning of year	144,856	82,356	'
Granted - above market price	'	62,500	'
Options outstanding at end of year	144,856	144,856	144,856
Options exercisable at end of year	109,969	88,689	109,969
Weighted average exercise price	'	'	'
Options outstanding at beginning of year	$6.66	$7.20	'
Granted - above market price	'	$6	'
Options outstanding at end of year	$6.66	$6.66	$6.66
Stockbased compensation expense	156,253	117,098	'
Unrecognized compensation expense	$52,949	'	$52,949
Period over which compensation expense will be recognized	'33 months	'	'

STOCKBASED_COMPENSATION_Summar

STOCKBASED COMPENSATION (Summary of Information for Options Outstanding and Exercisable by Exercise Price Range) (Details) (USD $)	12 Months Ended
	Aug. 31, 2013
Employees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	1,049,249
Outstanding, weighted average remaining contractual life, years	'5 years 7 months 28 days
Outstanding, weighted average exercise price	$4.13
Outstanding, aggregate intrinsic value	$3,379,544
Number exercisable	870,883
Exercisable, weighted average remaining contractual life, years	'4 years 11 months 1 day
Exercisable, weighted average exercise price	$3.72
Exercisable, aggregate intrinsic value	3,113,790
Nonemployees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	144,856
Outstanding, weighted average remaining contractual life, years	'3 years 11 months 1 day
Outstanding, weighted average exercise price	$6.66
Outstanding, aggregate intrinsic value	151,785
Number exercisable	109,969
Exercisable, weighted average remaining contractual life, years	'3 years 6 months 18 days
Exercisable, weighted average exercise price	$6.40
Exercisable, aggregate intrinsic value	128,283
$0.012 [Member] | Employees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	280,114
Outstanding, weighted average remaining contractual life, years	'11 months 5 days
Outstanding, weighted average exercise price	$0.01
Outstanding, aggregate intrinsic value	2,038,670
Number exercisable	290,114
Exercisable, weighted average remaining contractual life, years	'11 months 5 days
Exercisable, weighted average exercise price	$0.01
Exercisable, aggregate intrinsic value	2,038,670
$4.08 to 6.00 [Member] | Employees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	668,335
Outstanding, weighted average remaining contractual life, years	'7 years 18 days
Outstanding, weighted average exercise price	$5.28
Outstanding, aggregate intrinsic value	1,340,874
Number exercisable	578,169
Exercisable, weighted average remaining contractual life, years	'6 years 8 months 27 days
Exercisable, weighted average exercise price	$5.43
Exercisable, aggregate intrinsic value	1,075,120
$4.08 to 6.00 [Member] | Nonemployees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	111,520
Outstanding, weighted average remaining contractual life, years	'3 years 9 months 15 days
Outstanding, weighted average exercise price	$5.93
Outstanding, aggregate intrinsic value	151,785
Number exercisable	93,301
Exercisable, weighted average remaining contractual life, years	'3 years 5 months 1 day
Exercisable, weighted average exercise price	$5.92
Exercisable, aggregate intrinsic value	128,283
$7.88 to 9.12 [Member] | Employees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	100,800
Outstanding, weighted average remaining contractual life, years	'9 years 7 months 13 days
Outstanding, weighted average exercise price	$7.88
Outstanding, aggregate intrinsic value	'
Number exercisable	12,600
Exercisable, weighted average remaining contractual life, years	'9 years 7 months 13 days
Exercisable, weighted average exercise price	$7.88
Exercisable, aggregate intrinsic value	'
$7.88 to 9.12 [Member] | Nonemployees [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number outstanding	33,336
Outstanding, weighted average remaining contractual life, years	'4 years 3 months 29 days
Outstanding, weighted average exercise price	$9.12
Outstanding, aggregate intrinsic value	'
Number exercisable	16,668
Exercisable, weighted average remaining contractual life, years	'4 years 3 months 29 days
Exercisable, weighted average exercise price	$9.12
Exercisable, aggregate intrinsic value	'

ACCOUNTS_PAYABLE_AND_ACCRUED_E2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) (USD $)	Aug. 31, 2013	Aug. 31, 2012
ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]	'	'
Service providers	$392,289	$580,714
Payroll and related expenses	58,652	16,459
Accounts payable and accrued expenses	$450,941	$597,173

RESEARCH_AND_DEVELOPMENT_EXPEN2

RESEARCH AND DEVELOPMENT EXPENSES, NET (Details) (USD $)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
RESEARCH AND DEVELOPMENT EXPENSES, NET [Abstract]	'	'	'
Clinical trials	$1,341,471	$1,298,310	$6,504,824
Payroll and consulting fees	447,195	385,646	2,368,728
Costs for registration of patents	106,687	110,811	558,297
Compensation costs in respect of options granted to employees, directors and consultants	346,961	98,688	3,268,842
Other	338,635	160,350	886,242
Less - grants from the OCS	-309,155	-372,959	1,782,445
Research and Development Expense	$2,271,794	$1,680,845	$11,804,488

GENERAL_AND_ADMINISTRATIVE_EXP2

GENERAL AND ADMINISTRATIVE EXPENSES (Details) (USD $)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
GENERAL AND ADMINISTRATIVE EXPENSES [Abstract]	'	'	'
Stockbased compensation expense	$372,258	$172,470	$2,421,664
Professional services	439,175	221,218	2,338,919
Consulting fees	259,670	159,136	1,230,570
Travel costs	127,196	71,529	673,126
Write off of debt	'	'	275,000
Business development	308,183	284,899	1,124,128
Payroll and related expenses	230,191	144,101	983,399
Insurance	43,399	22,375	162,320
Other	252,057	127,436	984,550
General and Administrative Expense	$2,032,129	$1,203,164	$10,193,676

FINANCIAL_INCOME_AND_EXPENSES_1

FINANCIAL INCOME AND EXPENSES (Details) (USD $)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
Financial income	'	'	'
Gain on sale of marketable securities (note 3)	$90,370	'	'
Changes in fair value of warrant liabilities	44,699	'	'
Income from interest	18,728	13,126	'
Other	26,698	'	'
Financial income	180,495	13,126	387,653
Financial expenses	'	'	'
Exchange of warrants	296,982	'	296,982
Changes in fair value of warrant liabilities	'	142,704	'
Exchange rate differences	2,804	35,067	'
Bank commissions	13,660	14,952	'
Other	'	6,400	'
Financial expenses	$313,446	$199,123	$693,826

TAXES_ON_INCOME_Narrative_Deta

TAXES ON INCOME (Narrative) (Details) (USD $)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Taxes On Income [Line Items]	'	'
Corporate tax rate	35.00%	'
Net operating loss carryforwards	$5,605,237	$4,896,605
Penalties related to tax contingencies	0	15,539
Subsidiary [Member]	'	'
Taxes On Income [Line Items]	'	'
Corporate tax rate	25.00%	'
Net operating loss carryforwards	$7,663,790	$5,905,361

TAXES_ON_INCOME_Schedule_of_De

TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details) (USD $)	Aug. 31, 2013	Aug. 31, 2012
TAXES ON INCOME [Abstract]	'	'
Net operating loss carryforward	$3,992,737	$3,190,152
Research and development expenses	338,908	18,008
Less - Valuation allowance	-4,331,645	-3,208,160
Net deferred tax assets	'	'

TAXES_ON_INCOME_Schedule_of_In

TAXES ON INCOME (Schedule of Income Taxes Included in the Income Statements) (Details) (USD $)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
TAXES ON INCOME [Abstract]	'	'	'
U.S.	$1,185,831	$599,067	$9,626,374
Outside U.S.	3,251,044	2,655,193	12,461,502
Loss before taxes on income	4,436,874	3,254,260	22,087,875
U.S.	-12,960	-7,569	67,392
Outside U.S.	-192,102	97,787	108,440
Taxes on income	($205,062)	$90,218	$35,714

TAXES_ON_INCOME_Schedule_of_Re

TAXES ON INCOME (Schedule of Reconciliation of Income Taxes) (Details) (USD $)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
TAXES ON INCOME [Abstract]	'	'	'
Loss before income taxes as reported in the consolidated statement of operations	($4,436,874)	($3,254,260)	($22,087,875)
Statutory tax benefit	-1,522,906	-1,138,991	-7,700,757
Change in the balance of the valuation allowance for deferred tax losses	902,509	516,749	3,573,334
Disallowable deductions	374,059	120,156	2,617,605
Increase in taxes resulting from different tax rates applicable to non U.S. subsidiary	276,338	502,086	1,588,322
Uncertain tax position	-205,062	90,218	23,210
Taxes on income	($205,062)	$90,218	$35,714

TAXES_ON_INCOME_Schedule_of_Un

TAXES ON INCOME (Schedule of Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
TAXES ON INCOME [Abstract]	'	'
Balance at Beginning of Year	$228,272	$138,054
Increase (decrease) in tax positions for prior years	-205,062	90,218
Balance at End of Year	$23,210	$228,272

RELATED_PARTIES_TRANSACTIONS_N

RELATED PARTIES - TRANSACTIONS (Narrative) (Details) (USD $)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Directors [Member]	'	'
Related Party Transaction [Line Items]	'	'
Amount of transaction	$39,361	$30,000
JV Agreement [Member]	'	'
Related Party Transaction [Line Items]	'	'
Salary	250,000	'
Car and cash bonus	60,000	'
Nadav Kidron [Member]	'	'
Related Party Transaction [Line Items]	'	'
Salary	200,000	'
Car and cash bonus	$20,000	'

RELATED_PARTIES_TRANSACTIONS_S

RELATED PARTIES - TRANSACTIONS (Schedule of Balances with Related Parties) (Details) (USD $)	12 Months Ended
	Aug. 31, 2013		Aug. 31, 2012
Related Party Transaction [Line Items]	'		'
Accounts Receivable	$4,530		$404
Nadav Kidron [Member]	'		'
Related Party Transaction [Line Items]	'		'
Accounts Receivable	3,153	[1]	'
KNRY [Member]	'		'
Related Party Transaction [Line Items]	'		'
Accounts Receivable	1,377		404
Accounts payable and accrued expenses	64,355		'
Expenses to related parties	$448,080		$318,271
[1]	Down payment for travel expenses.

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)	12 Months Ended		137 Months Ended	2 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013	Nov. 25, 2013	Nov. 25, 2013
				Subsidiary [Member]	Advisor [Member]
Subsequent Event [Line Items]	'	'	'	'	'
Shares of stock sold	'	'	'	1,025,991	'
Value of shares of stock sold	'	'	'	$43,208	'
Percentage of D.N.A. shares owned	'	'	'	10.60%	'
Common stock issued for services	$244,457	$107,860	$1,400,413	'	$10,000